

ARTHRITIS & RHEUMATISM

OFFICIAL JOURNAL OF THE AMERICAN RHEUMATISM ASSOCIATION
SECTION OF THE ARTHRITIS FOUNDATION

CONTENTS VOLUME 21, 1978

VOL. 21	JANUARY-FEBRUARY	No. 1
Radiographic Abnormalities of Rheumatoid Arthritis in Patients with Diffuse Idiopathic Skeletal Hyperostosis <i>Donald Resnick, John Curd, Robert F. Shapiro, and Kenneth B. Wiesner</i>		1
Migrainous Phenomena in Systemic Lupus Erythematosus <i>Kenneth D. Brandt and Simmons Lessell</i>		7
Direct Evidence for Circulating DNA/Anti-DNA Complexes in Systemic Lupus Erythematosus <i>John S. Davis, Stephanie M. Godfrey, and John B. Winfield</i>		17
Comparative Studies of Antilymphocyte, Antipolynucleotide, and Antiviral Antibodies among Families of Patients with Systemic Lupus Erythematosus <i>O. Folomeeva, V. A. Nassonova, A. S. Alekberova, N. Talal, and R. C. Williams, Jr.</i>		23
Homozygous C2 Deficiency with Fulminant Lupus Erythematosus: Severe Nephritis via the Alternative Complement Pathway <i>Anita Gewurz, Thomas F. Lint, Jimmy L. Roberts, Howard Zeitz, and Henry Gewurz</i>		28
Computer Analysis of Factors Influencing Frequency of Infection in Systemic Lupus Erythematosus <i>Ellen Ginzler, Herbert Diamond, David Kaplan, Max Weiner, Michael Schlesinger, and Mitchel Seleznick</i> ..		37
Effect of Systemic Lupus Erythematosus Antibodies against DNA on RNA Synthesis <i>Olga V. Makarova</i>		45
Impaired Immunoglobulin Synthesis by Peripheral Blood Lymphocytes in Systemic Lupus Erythematosus <i>Kenneth M. Nies and James S. Louie</i>		51
Oral Mucosal Ulceration in Systemic Lupus Erythematosus <i>Jeffrey D. Urman, Mitchell B. Lowenstein, Micha Abeles, and Arthur Weinstein</i>		58
Muscle Disease in Progressive Systemic Sclerosis: Diagnostic and Therapeutic Considerations <i>Philip J. Clements, Daniel E. Furst, David S. Campion, Anthony Bohan, Robert Harris, Joshua Levy, and Harold E. Paulus</i>		62
Association between HLA-BW38 and Peripheral Psoriatic Arthritis <i>L. R. Espinoza, F. B. Vasey, J. H. Oh, R. Wilkinson, and C. K. Osterland</i>		72
Fat Droplets and Synovial Fluid Leukocytosis in Traumatic Arthritis <i>Jimmy Graham and John A. Goldman</i>		76
Pathogenesis of Chronic Inflammation in Experimental Ferritin-Induced Arthritis. IV. Immuno-Electron Microscopic Techniques in the Study of Articular Collagenous Tissues <i>Osamu Ohno, Hiroomi Tateishi, and T. Derek Cooke</i>		81
Intratendon Sheath Corticosteroid Treatment of Rheumatoid Arthritis-Associated and Idiopathic Hand Flexor Tenosynovitis <i>Robert G. Gray, Iris M. Kiem, and Norman L. Gottlieb</i>		92
Susceptibility of Rheumatoid and Nonrheumatoid Synovial Cells to Antibody-Dependent Cell-Mediated Cytotoxicity <i>Marie M. Griffiths, Charles B. Smith, and Barbara J. Pepper</i>		97
Kinetic Studies of Phagocytosis. I. The Serum Independent Particle Uptake by PMN from Patients with Rheumatoid Arthritis and Systemic Lupus Erythematosus <i>R. Hällgren, L. Håkansson, and P. Venge</i>		107

Drugs Affecting the Release of Rheumatoid Factor in a Plaque-Forming Cell Assay <i>Terry L. Moore, Dick L. Robbins, Jean E. Rose, and John H. Vaughan</i>	114
Serum Antiimmunoglobulins Reactive with Human and Rabbit IgG in Rheumatoid Arthritis and Other Conditions <i>Diana J. Stankaitienė, Alfonsas A. Matulis, Henrikas Guobys, and Janina P. Jusėnaitė</i>	120
Micromerement of Plasma Salicylate in Arthritic Children <i>Jerry C. Jacobs and Michael Pesce</i>	129
Methyl Ester of N-Formylmethionyl-Leucyl-Phenylalanine: Chemotactic Responses of Human Blood Monocytes and Inhibition of Gold Compounds <i>Peter P. K. Ho, Anna L. Young, and George L. Southard</i>	133
Case Report: Proliferative Synovitis in Hemophilia: Biochemical and Morphologic Observations <i>Carlo L. Mainardi, Peter H. Levine, Zena Werb, and Edward D. Harris, Jr.</i>	137
Case Report: Shoulder Swelling in Rheumatoid Arthritis Secondary to Subacromial Bursitis <i>Kent A. Huston, Audrey M. Nelson, and Gene G. Hunder</i>	145
Case Report: Hemarthrosis as the Presenting Manifestation of True Myeloma Joint Disease <i>Gregorio Mintz, Elsa J. Robles-Saavedra, Rubén D. Enriquez, F. Javier Jiménez, and Ma. Lourdes Juárez</i>	148
Editorial: Future Research Directions <i>J. Claude Bennett</i>	152
Future Research Directions: Amyloidosis: Current Trends in its Investigation <i>Alan S. Cohen, Edgar S. Cathcart, and Martha Skinner</i>	153
Radiologic Vignette No. 2: The Diagnostic Value of Buttressing of the Femoral Neck <i>William Martel and Ethan M. Braunstein</i>	161
Government Affairs <i>Roland W. Moskowitz</i>	165
Letters.....	167
Book Reviews.....	175
ARA Announcements.....	176

VOL. 21

MARCH

No. 2

Neoantigen of the Membrane Attack Complex of Human Complement: Occurrence on Peripheral Blood Leukocytes from Patients with Systemic Lupus Erythematosus <i>John G. Curd, John S. Sundsmo, William P. Kolb, Harry G. Bluestein, and Hans J. Müller-Eberhard</i>	177
Familial Lupus: Family Studies of HLA and Serologic Findings <i>Leslie G. Cleland, David A. Bell, Martin Willons, and Bruce C. Saurino</i>	183
Normal Distribution of Acetylation Phenotypes in Systemic Lupus Erythematosus <i>Johnathan Vansant, Raymond L. Woosley, J. Thomas John, and John S. Sergeant</i>	192
Effect of Altered Lymphocyte Function on Immunologic Disorders in NZB/NZW Mice. III. Acceleration of Disease by Thymosin <i>Jagdish Mehta, Linda Knotts, Carolyn Craig, Sharon Burkholder, Christine Miller, and Bevra Hahn</i>	196
Therapeutic Studies in NZB/NZW Mice. VI. Age-Dependent Effects of Concanavalin A Stimulated Spleen Cell Supernate <i>Alfred D. Steinberg, Randall Krakauer, James L. Reinertsen, Lynell W. Klassen, David Ilfeld, J. Patton Reeves, Gary W. Williams, and Tatiana Antonovych</i>	204
Hand Structure and Function in an Industrial Setting: Influence of Three Patterns of Stereotyped, Repetitive Usage <i>Norin M. Hadler, Dennis B. Gillings, Harold R. Imbus, Peter M. Levitin, Diane Makuc, Peter D. Utsinger, William J. Yount, Derwood Slusser, and Nancy Moskovitz</i>	210
Carpal Tunnel Syndrome with Polymyalgia Rheumatica <i>Tahir Ahmed and Alan I. Braun</i>	221
Automated Rheumatoid Factor Assay in a Population of Patients with Rheumatic Disease <i>Eric P. Gall, David W. Templin, and William R. Dito</i>	224
Psychosocial Factors in Juvenile Rheumatoid Arthritis <i>Monica Jean Henoch, Jean W. Batson, and John Baum</i>	229

Quantitative Sacroiliac Scintigraphy in Patients with Crohn's Disease <i>Paul Davis, Alan B. R. Thomson, and Brian C. Lentle</i>	234
Hyporesponsiveness of Lymphocytes to Virus Antigens in Rheumatoid Arthritis <i>Robert E. Wolf</i>	238
Demonstration of Anticollagen Antibodies in Rheumatoid Arthritis Synovial Fluids by ¹⁴ C-Radioimmunoassay <i>Johannes Menzel, Carl Steffen, Gernot Kolarz, Marina Kojer, and Josef Smolen</i>	243
Immunopathologic Studies of Rheumatoid Arthritis. I. Absence of Complement-Dependent Cytotoxicity of Rheumatoid Sera for Rheumatoid Synovial Cell Cultures <i>Stephen A. Paget, Karen Anderson, and Paul E. Phillips</i>	249
Thrombocytosis and Platelet Aggregates in the Circulation of Adjuvant Arthritic Rats <i>Peter Görög and Iren B. Kovács</i>	256
Arthritis Rounds: Multiple Myeloma Complicating the Course of Seronegative Systemic Lupus Erythematosus <i>Edward Jordan, Stephen L. Burnstein, John J. Calabro, and Edward S. Henderson</i>	260
Discussion: <i>Charles L. Christian</i>	264
Current Comment: Type C Viruses and Systemic Lupus Erythematosus <i>Joseph A. Markenson and Paul E. Phillips</i>	266
Case Report: Vertebral Sarcoidosis with Paravertebral Ossification <i>Susan G. Perlman, John Damergis, Phillip Witorsch, F. Donald Cooney, Stephen F. Gunther, and Werner F. Barth</i>	271
Editorial	277
Letters	279
Book Reviews	285
ARA Announcements	287

VOL. 21

APRIL

No. 3

Serologic Studies in Patients with Systemic Lupus Erythematosus and Central Nervous System Dysfunction <i>John B. Winfield, Carolyn M. Brunner, and David Koffler</i>	289
Lymphopenia in Systemic Lupus Erythematosus: Clinical, Diagnostic, and Prognostic Significance <i>Santiago J. Rivero, Efraim Díaz-Jouanen, and Donato Alarcón-Segovia</i>	295
Monozygotic Twins with Klinefelter's Syndrome Discordant for Systemic Lupus Erythematosus and Symptomatic Myasthenia Gravis <i>Joseph P. Michalski, Steven M. Snyder, Rima L. McLeod, and Norman Talal</i>	306
Comparison of the Presence of Immune Complexes in Felty's Syndrome and Rheumatoid Arthritis <i>Mario Andreis, Eric R. Hurd, Joseph Lospalluto, and Morris Ziff</i>	310
Studies of the Effects of Pregnancy Serum on Polymorphonuclear Leukocyte Functions <i>Robert H. Persellin and June K. Leibfarth</i>	316
Decreased Lymphocyte Response to PHA, Con-A, and Calcium Ionophore (A23187) in Patients with RA and SLE, and Reversal with Levamisole in Rheumatoid Arthritis <i>Morton A. Scheinberg, Leonilda Santos, Nelson F. Mendes, and Chloé Musatti</i>	326
Synthesis by an Established Lymphocyte Cell Line from a Rheumatoid Synovium <i>Bruce C. Gilliland, Denys K. Ford, and Mart Mannik</i>	330
Relationship of HLA-Dw3 and HLA-B8 to Sjögren's Syndrome <i>Kenneth H. Fye, Paul I. Terasaki, Joseph P. Michalski, Troy E. Daniels, Gerhard Opelz, and Norman Talal</i>	337
Fibrinogen Turnover in Progressive Systemic Sclerosis <i>Geoffrey M. Gratwick, Ronald Klein, John S. Sergeant, and Charles L. Christian</i>	343
Rapid Assessment of ^{99m} Tc-Perchnetate Uptake in the Knee Joint as a Parameter of Inflammatory Activity <i>Agnes M. TH. Boerbooms and Wil C. A. M. Buys</i>	348
Immunoglobulin in Tophi and on the Surface of Monosodium Urate Crystals <i>Peter Hasselbacher and H. Ralph Schumacher</i>	353
Non-Giant Cell Temporal Arteritis: Three Cases and a Review of the Literature <i>G. James Morgan, Jr. and Edward D. Harris, Jr.</i>	362

Idiopathic Multicentric Osteolysis: Report of an Affected Father and Son <i>Michael P. Whyte, William A. Murphy, Michael Kleerekoper, Steven L. Teitelbaum, and Louis V. Avioli</i>	367
Current Comment: Prevalence of Rheumatic Diseases as Causes of Disability and Complaints by Ambulatory Patients <i>Michael D. Reynolds</i>	377
Arthritis Rounds: Ankylosing Spondylitis with Subsequent Development of Rheumatoid Arthritis, Sjögren's Syndrome, and Rheumatoid Vasculitis <i>Michael D. Clayman and James L. Reinertsen</i>	383
Discussion <i>E. G. L. Bywaters</i>	388
Letters	390
Book Reviews	398
ARA Announcements	400

VOL. 21

MAY

NO. 4

Total Hip Replacement in Children with Arthritis <i>B. H. Singen, A. S. Isaacson, B. H. Bernstein, M. J. Patzakis, H. K. Kornreich, K. K. King, and V. Hanson</i>	401
Analysis of DNA Structure by Hydroxyapatite Columns and Ethidium Bromide Fluorescence Techniques: A Comparative Study and Effect on DNA Binding <i>Paul Davis, Michael Burrington, Anthony S. Russell, and A. Richard Morgan</i>	407
Effect of the Anti-Estrogen, Nafoxidine, on NZB/W Autoimmune Disease <i>Madeleine Duwic, Alfred D. Steinberg, and Lynell W. Klassen</i>	414
Collagen in the Cellular and Fibrotic Stages of Scleroderma <i>Raul Fleischmajer, Steffan Gay, Wilhelm N. Meigel, and Jerome S. Perlish</i>	418
Pathologic Features of a Familial Arthropathy Associated with Congenital Flexion Contractures of Fingers <i>Balu H. Athreya and H. Ralph Schumacher</i>	429
Light Chain Heterogeneity of 19S and 7S Anti- γ -Globulins in Rheumatoid Arthritis and Subacute Bacterial Endocarditis <i>Dennis A. Carson and Simon Lawrance</i>	438
Comparison of Gold Levels and Distribution in Guinea Pig Serum <i>H. Kamel, D. H. Brown, J. M. Ottaway, W. E. Smith, J. Cottney, and A. J. Lewis</i>	441
Inorganic Pyrophosphatase Activity of the Synovial Fluid: Kinetic and Clinical Study <i>Sergio Jacobelli, Ana Maria Kettlun, and Mario Sapag-Hagar</i>	447
Enhancement of Urate Solubility by Connective Tissue. I. Effect of Proteoglycan Aggregates and Buffer Cation <i>Elaine Perricone and Kenneth D. Brandt</i>	453
The Growth Kinetics of Synovial Fibroblastic Cells from Inflammatory and Noninflammatory Arthropathies <i>Tassos P. Anastassiades, Janice Ley, Anne Wood, and David Irwin</i>	461
Vertebral Ankylosing Hyperostosis (Forestier's Disease) and HLA Antigens in Pima Indians <i>Alan M. Spagnola, Peter H. Bennett, and Paul I. Terasaki</i>	467
Age, Sex, and Race Effects on Mortality from Systemic Lupus Erythematosus in the United States <i>Richard A. Kaslow and Alfonse T. Masi</i>	473
Current Comment: Sex Effects in Systemic Lupus Erythematosus: A Clue to Pathogenesis <i>Alfonse T. Masi and Richard A. Kaslow</i>	480
Radiologic Vignette No. 3: Spinal Pseudoarthrosis: A Complication of Ankylosing Spondylitis <i>William Martel</i>	485
Letters	491

Clinical Features of the Arthritis of Mixed Connective Tissue Disease <i>James T. Halla and Joe G. Hardin</i>	497
Autoimmune Neutropenia in Systemic Lupus Erythematosus <i>Gordon Starkebaum, Thomas H. Price, Minako Y. Lee, and William P. Arend</i>	504
Chrysotherapy in Psoriatic Arthritis: Efficacy and Toxicity Compared to Rheumatoid Arthritis <i>Bonnie B. Dorwart, Eric P. Gall, H. Ralph Schumacher, and Ronald E. Krauser</i>	513
Electron Microscopic Morphology of Immunoglobulin Aggregates and Their Interactions in Rheumatoid Articular Collagenous Tissues <i>Osamu Ohno and T. Derek Cooke</i>	516
A Subgroup of Ankylosing Spondylitis Associated with HLA-B7 in American Blacks <i>Muhammad A. Khan, Irving Kushner, and William E. Braun</i>	528
Future Research Directions: The Infectious Etiology of Rheumatoid Arthritis: New Considerations <i>J. Claude Bennett</i>	531
Proceedings of the 42nd Annual Meeting of the American Rheumatism Association: Abstracts of Papers Presented	539
Letters	607
Books Received	614
ARA Announcements	615

Proceedings of the Conference on New Directions for Research in Systemic Lupus Erythematosus	S1-S240
--	---------

Introduction to the Joseph J. Bunim Memorial Lecture <i>Colon H. Wilson, Jr.</i>	617
Joseph J. Bunim Memorial Lecture: Seronegative Polyarthritis: A Unified Concept <i>V. Wright</i>	619
Studies on Heterophile Antibodies in Rheumatoid Arthritis <i>Tomoe Nishimaki, Kyoichi Kano, and Felix Milgrom</i>	634
Studies on Immune Complexes in Rheumatoid Arthritis <i>Tomoe Nishimaki, Kyoichi Kano, and Felix Milgrom</i>	639
A Controlled Study of ANA+ RF- Arthritis <i>Julius E. Linn, Joe G. Hardin, and James T. Halla</i>	645
A Study of HLA Antigens in Adults with Acute Rheumatic Fever <i>Garvin C. Murray, Milka M. Monteil, and Robert H. Persellin</i>	652
Studies of Immune Functions of Patients with Systemic Lupus Erythematosus. I. Dysfunction of Suppressor T-Cell Activity Related to Impaired Generation of, Rather than Response to, Suppressor Cells <i>Tsuyoshi Sakane, Alfred D. Steinberg, and Ira Green</i>	657
Androgenic Status of Males with Systemic Lupus Erythematosus <i>Neil I. Stahl and John L. Decker</i>	665
Horizontal Splitting in Patellar Articular Cartilage <i>G. Meachim and G. Bentley</i>	669
Antigen-Induced Arthritis: Decreased Proteoglycan Content and Inhibition of Proteoglycan Synthesis in Articular Cartilage <i>Dennis A. Lowther, John D. Sandy, Vivien B. Santer, and Heather L. G. Brown</i>	675

Hematologic and Serologic Studies in 6-Sulfanilamidoindazole Arthritis <i>Morgan L. Miller, Cecil O. Samuelson, and John R. Ward</i>	681
Mixed Lymphocyte Reaction in Healthy Women with Rheumatoid Factor: Lack of Association with HLA-Dw4 <i>Edgar Engleman, Ernest E. Sponzilli, Marion E. Batey, Savitri Ramcharan, and Hugh O. McDevitt</i>	690
Interrelationship between Stimulation of Prostaglandin E and Hyaluronate Production by Poly (I) · Poly (C) and Interferon in Synovial Fibroblast Culture <i>Michael Yaron, Ilana Yaron, Chana Wiletzki, and Uriel Zor</i>	694
The Amyloidosis of Juvenile Rheumatoid Arthritis—Comparative Studies in Polish and American Children. I. Levels of Serum SAA Protein <i>Anna Maria Filipowicz-Sosnowska, Katarzyna Roztropowicz-Denisiewicz, C. Julian Rosenthal, and John Baum</i>	699
Ocular Chrysis Correlated with Gold Concentrations in the Crystalline Lens during Chrysotherapy <i>Norman L. Gottlieb and James C. Major</i>	704
Mixed Connective Tissue Disease in Siblings <i>John R. Horn, Janet J. Kapur, and Sara E. Walker</i>	709
Atypical Axial Osteomalacia: Report of Four Cases with Two Having Features of Ankylosing Spondylitis <i>A. M. Nelson, B. L. Riggs, and J. O. Jowsey</i>	715
Case Report: Idiopathic Charcot Joint of the Elbow <i>A. T. Blanford, S. P. Keane, D. J. McCarty, and J. W. Albers</i>	723
Current Comment: The Satellite Arthritis Clinic <i>Robert S. Pinals</i>	727
Arthritis Rounds: Marrow Aplasia Induced by Colchicine: A Case Report <i>Yong K. Liu, Richard Hymowitz, and Michael G. Carroll</i>	731
Discussion <i>Stephen E. Malawista</i>	735
Letters	737
ARA Announcements	743

VOL. 21

SEPTEMBER-OCTOBER

NO. 7

Collagenase Production by Cultures Containing Multinucleated Cells Derived from Synovial Fibroblasts <i>Constance E. Brinckerhoff and Edward D. Harris, Jr.</i>	745
Boundary Lubricating Ability of Synovial Fluid in Degenerative Joint Disease <i>Warren H. Davis, Jr., S. L. Lee, and Leon Sokoloff</i>	754
Correlation between Articular Cartilage Collagenase Activity and Osteoarthritis <i>Michael G. Ehrlich, Patricia A. Houle, Gloria Vigliani, and Henry J. Mankin</i>	761
Differential Effects of Propranolol on Lymphocyte Rosette Formation and Response to Plant Mitogens <i>James V. Dunne, Clarence J. Peters, Terry L. Moore, and John H. Vaughan</i>	767
Synovial Fluid Lactic Acid: A Diagnostic Aid in Septic Arthritis <i>Itzhak Brook, Michael J. Reza, Kenneth S. Bricknell, Rodney Bluestone, and Sydney M. Finegold</i>	774
Temporal Arteriography: Analysis of 21 Cases and a Review of the Literature <i>Lawrence F. Layfer, Barbara F. Banner, Michael S. Huckman, Lorne S. Grainer, and Harvey E. Golden</i>	780
Chrysotherapy: Suppression of Immunoglobulin Synthesis <i>Arthur Lorber, Timothy Simon, John Leeb, Alan Peter, and Stuart Wilcox</i>	785
Effect of Inherited Deficiency of the Fifth Component of Complement on Arthritis Induced in Mice by <i>Mycoplasma Pulmonis</i> <i>E. Keystone, D. Taylor-Robinson, C. Pope, G. Taylor, and P. Furr</i>	792
Herpes Zoster in Patients with Systemic Lupus Erythematosus <i>Haralampos M. Moutsopoulos, John D. Gallagher, John L. Decker, and Alfred D. Steinberg</i>	798
Identification and Characterization of Two New Soluble Nuclear Antigens Reactive with Sera of Patients with Connective Tissue Diseases <i>Shoji Miyawaki, Kiichi Kohmoto, Noriyuki Kurata, and Tadashi Ofuji</i>	803
Gastrointestinal Systemic Sclerosis in Serologic Mixed Connective Tissue Disease <i>Daniel A. Norman and Roy M. Fleischmann</i>	811

Relative Reactivities of Rheumatoid Factors in Serum and Cells: Evidence for a Selective Deficiency in Serum Rheumatoid Factor	
<i>Dick L. Robbins, Terry L. Moore, Dennis A. Carson, and John H. Vaughan</i>	820
The Costs of Rheumatoid Arthritis: A Patient-Oriented Study of Chronic Disease Costs	
<i>Robert F. Meenan, Edward H. Yelin, Curtis J. Henke, David L. Curtis, and Wallace V. Epstein</i>	827
Case Report: Regional Migratory Osteoporosis: A Denervation Disease	
<i>W. Clay McCord, Kenneth M. Nies, David S. Campion, and James S. Louie</i>	834
Case Report: Central Retinal Vein Occlusion Complicating Systemic Lupus Erythematosus	
<i>Michael Silverman, Marvin J. Lubeck, and Walter G. Briney</i>	839
Case Report: Hemochromatotic Arthropathy Mimicking Rheumatoid Arthritis: A Case with Subcutaneous Nodules, Tenosynovitis, and Bursitis	
<i>William G. Bensen, Carl A. Laskin, Hugh A. Little, and Adel G. Fam</i>	844
Current Comment: Immunologic Sex Differences and the Female Predominance in Systemic Lupus Erythematosus	
<i>Robert D. Inman</i>	849
Future Research Directions: Autoimmunity and the Immunologic Network	
<i>Norman Talal</i>	853
Letters	862
Book Reviews	870
Books Received	871
ARA Announcements	872

Vol. 21

NOVEMBER-DECEMBER

No. 8

Reactivities of Systemic Lupus Erythematosus Sera with Cellular and Virus Antigen Preparations	
<i>Theodore Pincus, Alfred D. Steinberg, Neil R. Blacklow and John L. Decker</i>	873
Search for Type-C Oncornavirus-Related Genetic Information in Tissues from Patients with Systemic Lupus Erythematosus	
<i>Gurmit S. Aulakh, John T. Hicks, W. John Martin and Paul E. Phillips</i>	880
HLA-C Locus Antigens in HLA-B27 Associated Arthritis	
<i>Frank C. Arnett, Marc C. Hochberg and Wilma B. Bias</i>	885
High Prevalence of HLA-Cw1 and Cw2 Antigens in Spondylarthritis	
<i>Franklin Kozin, Rene Duquesnoy, Glenn E. Rodey, Robert W. Lightfoot, Jr. and Lawrence M. Ryan</i>	889
Mechanisms of Cellular Interaction with Monosodium Urate Crystals: IgG-Dependent and IgG-Independent Platelet Stimulation by Urate Crystals	
<i>Mark H. Ginsberg and Frank Kozin</i>	896
Humoral Immune Stimulation and Antiepitheial Antibodies in Yersinia Infection	
<i>Marianne Gripenberg, Aaro Miettinen, Pekka Kurki and Evert Linder</i>	904
Involvement of Prostaglandins from Rheumatoid Synovium in Inhibition of Articular Cartilage Metabolism	
<i>L. Lippiello, K. Yamamoto, D. Robinson and H. J. Mankin</i>	909
Fate of Antigen after Intravenous and Intraarticular Injection into Rabbits	
<i>Hal Mitnick, Sylvia Hoffstein and Gerald Weissman</i>	918
Complement-Fixing Hidden Rheumatoid Factor in Children with Benign Rheumatoid Nodules	
<i>Terry L. Moore, Robert W. Dorner and Jack Zuckner</i>	930
Complement-Fixing Hidden Rheumatoid Factor in Juvenile Rheumatoid Arthritis	
<i>Terry L. Moore, Jack Zuckner, Andrew R. Baldassare, Terry D. Weiss and Robert W. Dorner</i>	935
Effects of Diphosphonates on Glycosaminoglycan Synthesis and Proteoglycan Aggregation in Normal Adult Articular Cartilage	
<i>Marshall Palmoski and Kenneth Brandt</i>	942
Reevaluation of the Ammonium Sulfate Assay for DNA Antibody	
<i>Robert L. Rubin, Joyce Lafferty and Ronald I. Carr</i>	950

Familial Deficiency of Two Subunits of the First Component of Complement: C1r and C1s Associated with a Lupus Erythematosus-Like Disease <i>Stanley L. Lee, Stanley L. Wallace, Richard Barone, Livia Blum and P. Harvey Chase</i>	958
Acute Hematogenous Osteomyelitis Progressing to Septic Synovitis and Eventual Pyarthrosis: The Vascular Pathway <i>Steven G. Atcheson and John R. Ward</i>	968
Case Report: Constrictive Pericarditis in Systemic Lupus Erythematosus: Demonstration of Immunoglobulins in the Pericardium <i>Edwin J. Jacobson and Michael J. Reza</i>	972
Case Report: Legionnaires' Disease in a Patient with Systemic Lupus Erythematosus <i>Ralph F. Jacox and I. Donald Stuard</i>	975
Case Report: Echovirus-Associated Polyarthrits: Report of a Case with Synovial Fluid and Synovial Histologic Characterization <i>J. Wolfe Blotzer and Allen R. Myers</i>	978
Case Report: Transverse Myelitis in Mixed Connective Tissue Disease <i>Terry D. Weiss, James S. Nelson, Robert M. Woolsey, Jack Zuckner and Andrew R. Baldassare</i>	983
Government Affairs: The Future of Federal Support for Health Research <i>Roland W. Moskowitz</i>	987
In Memoriam: Dr. Jacques Forestier <i>Milovan Rakic</i>	989
Letters.....	991
ARA Announcements.....	1000
Annual Indexes	1001

VOL. 21

NOVEMBER-DECEMBER

No. 8 SUPPLEMENT

Twenty-Third Rheumatism Review.....	R1-R312
-------------------------------------	---------

INDEXES

AUTHOR INDEX

Page numbers in *italics* refer to abstracts. Authors published in the June supplement are indexed in that volume.

A

Abel T, 539
 Abeles M, 58
 Abrass CK, 539
 Adams LE, 565
 Adelstein E, 604
 Agnello V, 540
 Ahmed T, 221
 Alarcón-Segovia D, 295, 493, 866
 Albers JW, 723
 Alekberova AS, 23
 Ally AI, 492
 Aldo-Benson M, 605
 Alspaugh MA, 540, 590
 Altman RD, 541, 576
 Ambanelli U, 396
 Anastassiades TP, 461
 Anderson K, 249, 582
 Andreis M, 310
 Andres C, 603
 Antonovych T, 204
 Appelboon T, 174
 Arbetter AE, 540
 Arend WP, 504
 Arinovich R, 742
 Arnett FC, 542, 885
 Arnold W, 603
 Arroyave CM, 542
 Arthur RE, 579
 Atcheson SE, 968
 Athreya BH, 429
 Aulakh GS, 880
 Austin TW, 574
 Avioli LV, 367
 Ayers RC, 557

B

Bacon PA, 560
 Bailey AJ, 545
 Baldassare AR, 579, 935, 983
 Baker MA, 585
 Ball GV, 870
 Ballou SP, 543
 Balow JE, 580
 Balow JL, 570
 Banner BF, 780
 Barada FA, 543
 Baraf HSB, 544
 Baratz M, 604
 Barnett EV, 574
 Barone R, 958
 Barth WF, 271
 Bartholomew FN, 544
 Bartholomew LE, 544, 588
 Batey ME, 690
 Batson JW, 229
 Baum J, 229, 699
 Bear RA, 554

Beighton P, 545
 Bell DA, 183, 545, 574
 Benderly A, 391
 Bennett JC, 152, 531, 557
 Bennett M, 603
 Bennett PH, 467
 Bennett RM, 546
 Bensen WG, 844
 Bentley G, 669
 Berg E, 396
 Berney S, 863
 Bernhard GC, 587
 Bernstein BH, 401, 593
 Bias WB, 542, 885
 Biegel A, 605
 Bishko F, 868
 Biundo JJ Jr, 590
 Black CM, 545
 Blacklow NR, 873
 Blanford AT, 723
 Blotzer JW, 978
 Bluestein HG, 177, 546
 Bluestone R, 175, 285, 774
 Blum L, 862, 958
 Boerbooms AMTH, 348
 Bohan A, 62
 Bole GG, 599
 Bong DA, 546
 Border WA, 539
 Bordwell B, 602
 Botzenhardt U, 547
 Bowden RE, 570
 Boyd R, 559
 Boyer RS, 547, 582
 Brandt KD, 7, 453, 575, 583, 942
 Braun AI, 221
 Braun WE, 528, 569
 Braunstein EM, 161
 Bresnahan B, 560
 Breth G, 995
 Brickness KD, 774
 Brighton CT, 566, 585
 Brinkerhoff CE, 547, 745
 Briney WG, 839
 Broder I, 280
 Brook I, 774
 Brown BW Jr, 576
 Brown DH, 441
 Brown HLG, 675
 Brown MD, 541
 Brumfield H, 549
 Brunner CM, 289
 Buchert P, 596
 Buchnall R, 560
 Bunch TW, 548
 Burkholder S, 196
 Burnstein SL, 260
 Burrington M, 407
 Buscher H, 174
 Buys WCM, 348
 Bywaters EGL, 388, 739

C

Calabro JJ, 167, 260
 Caldwell DS, 544
 Calin A, 548
 Campion DS, 62, 834, 994
 Carboni JM, 564
 Cardella CJ, 554
 Carlo JR, 549
 Carpenter JC, 549
 Carr ME, 562
 Carr RI, 587, 950
 Carroll MG, 731
 Carson DA, 438, 550, 593, 820
 Cassidy JT, 554
 Castor CW, 550
 Cathcart ES, 153, 592, 603
 Catherole L, 545
 Chandler RW, 575
 Chang Y, 170
 Chase PH, 958
 Cheung HS, 551
 Chia D, 574
 Chodirker WB, 585
 Chow D, 598
 Christian CL, 264, 343
 Chused TM, 551, 580
 Classen JN, 606
 Clayman MD, 383
 Cleland LG, 183
 Clements PJ, 62, 557, 994
 Cline MJ, 560
 Clough JD, 391
 Cohen AS, 153
 Cohen PL, 551
 Cook EH, 608
 Cooke CR, 600
 Cooke TDV, 81, 516, 556
 Combs JJ, 548
 Cooney FD, 271
 Cottney J, 441
 Cottrell WH, 551
 Craig C, 196
 Crissman JD, 596
 Crockson AP, 491
 Crockson RA, 491
 Crowe W, 391
 Cummings NA, 596
 Cunnane SC, 492
 Curd J, 1, 177
 Curtis DL, 827

D

Damergis J, 271
 D'Angelo WA, 576
 Daniels TE, 337, 584
 Davis JS, 17
 Davis P, 234, 407, 552
 Davis WH, 754
 Dayer JM, 552

Decker JL, 570, 586, 594, 665, 798, 873
 DeHeer DH, 567
 DeHoratius RJ, 553, 561
 de Kasep GI, 540
 De La Fuente JR, 493
 Delahaye RP, 993
 Dell'Italia LJ, 167
 Denko CW, 496
 Diamond HS, 37, 553
 Diaz-Jouanan E, 295, 493
 Dimant J, 393
 Disney TF, 574
 Dito WR, 224
 Djaldetti M, 608
 Dorner RW, 579, 930, 935
 Dorwart BB, 513
 Douglas SD, 601
 Doury P, 993
 Dunne JV, 767
 DuPont B, 558
 Duquesnoy R, 889
 Duvic M, 414
 Dyck RF, 554

E

Edwards NL, 554
 Ege GN, 585
 Ellman MH, 613
 Ely PH, 599
 Emery H, 599
 Emlen W, 555
 Engel AG, 548
 Engleman E, 690
 Enriquez RD, 148, 578
 Epstein WV, 827
 Espinoza LR, 72
 Evans JA, 555
 Exaire E, 578

F

Falbo A, 588
 Fam AG, 844
 Famaey JP, 174
 Farber N, 599
 Farmer PM, 393
 Farrar JJ, 571
 Faure G, 997
 Feigenbaum SL, 575, 577
 Ferguson L, 613
 Ferraccioli GF, 396
 Filipowicz-Sosnowska AM, 699
 Filo R, 575
 Finegold SM, 774
 Fisher WD, 556
 Fleischmajer R, 418
 Fleischmann RM, 811
 Foad BS, 565
 Folomeeva O, 23

Ford DK, 330
 Fotino M, 558
 Fox IH, 554, 603
 Fox R, 548
 Frank MM, 563, 580
 Frayha RA, 611, 741
 Friedman DM, 556
 Fries JF, 576, 600, 601
 Fritzler MJ, 556, 591
 Furr P, 792
 Furst DE, 62, 557
 Fuson EW, 558
 Fuzesi L, 600
 Fye KH, 337, 584

G

Gagliardi S, 868
 Gale R, 557
 Gall EP, 224, 513
 Gallagher JD, 798
 Ganuza C, 605
 Garcia-Morteo O, 868
 Gargano FP, 541
 Gaucher A, 997
 Gay S, 418
 Gelfand E, 603
 Gerber RC, 548
 Getzy L, 586
 Gewurz A, 28
 Gewurz H, 28
 Gibofsky A, 558
 Gibson DJ, 548
 Gilliam JN, 566
 Gilliland BC, 330, 581
 Gillings DB, 210
 Ginsberg MH, 558, 896, 995
 Ginzler E, 37
 Gladman DD, 559
 Glasscock RJ, 539
 Godfrey SM, 17
 Godzeski CW, 559
 Gofton JP, 869
 Goldberg LS, 560
 Goldberg VM, 560, 579, 586
 Golden HE, 780
 Goldman JA, 72
 Goldstein IM, 583
 Good A, 597
 Goodwin JS, 561
 Gordon DA, 280, 554, 585
 Gorog P, 256
 Gottlieb NL, 92, 282, 704
 Graham J, 76
 Granberry WM, 561
 Granier LS, 780
 Granier R, 993
 Gratwick GM, 343
 Gray RG, 92, 494
 Graze P, 557
 Green I, 657
 Griffiths MM, 97
 Gripenberg M, 904
 Gruskin BJ, 168
 Guggenheim SJ, 595
 Gunther SF, 271
 Guobys H, 120
 Guzman L, 742

H

Hadler NM, 210, 562
 Hahn B, 196
 Hakansson L, 107
 Halla JT, 497, 562, 645
 Hallgren R, 107
 Halushka PV, 571
 Halverson PB, 563
 Hamburger MI, 563
 Hammerman D, 559
 Hansen JA, 558
 Hanson V, 401, 573, 593
 Hardin JA, 564
 Hardin JG, 497, 562, 645, 871
 Harris ED, Jr, 137, 362, 547, 591, 745
 Harris R, 62
 Harth M, 574
 Hashimoto EG, 581
 Hasselbacher P, 353, 565, 740
 Hastings DE, 555
 Hazard GW, 167
 Healey LA, 565
 Henderson ES, 260
 Henke CJ, 827
 Henoch MJ, 229
 Herman JH, 596
 Hess EV, 397, 565
 Hicks JT, 880
 Himenstein M, 283
 Ho PPK, 133
 Hochberg MC, 542, 885
 Hoffstein S, 918
 Hofftein S, 594
 Holbrook T, 593
 Holden D, 553
 Holmes EW, 544
 Hoover PL, 592
 Hopper J, 598
 Horn JR, 709
 Horrobin DF, 492
 Horton JE, 571
 Horwitz DA, 543
 Houle PA, 761
 Howell DS, 579, 588, 597
 Hübscher O, 868
 Huckman MS, 780
 Hughes GRV, 560, 597
 Hunder GG, 145, 175
 Hungerford DS, 606
 Hurd ER, 310, 566
 Huston KA, 145
 Hymowitz R, 731

I

Ilfeld D, 204
 Ilstrup DM, 548
 Imbus HR, 210
 Inman R, 582, 849
 Irwin D, 461
 Isaacson AS, 401
 Israel H, 561

J

Jackson EA, 992
 Jacobelli S, 447

Jacobs JC, 129
 Jacobson EJ, 972
 Jacox RF, 975
 Jacquot JM, 996
 Jasin HE, 598
 Jee WS, 581
 Jensen F, 593
 Jimenez FJ, 148
 Jimenez J, 578
 Jimenez SA, 566
 Joachim C, 600
 John JT, 192
 Johnson AH, 580, 586
 Johnson M, 554
 Jones JV, 567
 Jones M, 596
 Jones T, 597
 Jordan E, 260
 Jowsey JO, 715
 Jubran F, 611
 Jusenaite J, 20

K

Kagen LJ, 568
 Kahaleh MB, 567
 Kaklamanis P, 279
 Kamel H, 441
 Kaminska J, 603
 Kang AH, 584
 Kano K, 634, 639
 Kaplan D, 37
 Kaplan F, 566
 Kaplan PE, 993
 Kaplan RA, 567
 Kaplan SB, 575, 577
 Kapur JJ, 709
 Kapusta MA, 568
 Karmali RA, 492
 Karmazyn M, 492
 Karthikeyan G, 862
 Kaslow RA, 473, 480
 Kassan SS, 568
 Katz A, 554, 585
 Kay DR, 599
 Keane SP, 723
 Keiser JR, 570
 Kettlun AM, 447
 Keystone EC, 539, 559, 569, 792
 Khan MA, 528, 569
 Kiem IM, 92
 Kilduff FJ, 167
 Kimberly RP, 570
 King KK, 401
 King R, 549
 King SR, 550
 Kirk KA, 564
 Klassen LW, 204, 414
 Kleerekoper M, 367
 Klein J, 547
 Klein R, 343
 Klippel JH, 546, 570, 586, 594
 Knotts L, 196
 Koehler BE, 280
 Koffler D, 289
 Kohmoto K, 803
 Kojer M, 243
 Kolarz G, 243

Kolb WP, 177
 Koopman WJ, 571
 Korn JH, 571
 Kornreich HK, 401
 Kourounakis L, 568
 Kovacs I, 256
 Kovalchik MT, 592, 595
 Kovarsky J, 865
 Kozin F, 558, 587, 889, 896
 Krakauer KA, 571
 Krakauer R, 204
 Krane SM, 552
 Krauser RE, 513
 Krohel G, 588
 Kunkel HG, 558
 Kurata N, 803
 Kurki P, 904
 Kushner I, 391, 528, 543, 569, 605

L

Lafferty J, 950
 Lamon EW, 557
 Landing B, 593
 Lanza FL, 572
 Laskin CA, 844
 Lawley TJ, 580
 Lawley TL, 563
 Lawrance S, 438, 550
 Layfer LF, 567, 572, 780
 Lee MY, 504
 Lee SL, 754, 958
 Leeb J, 785
 Leers SA, 167
 Lehman TJA, 573
 Leibfarth JK, 316
 Lentle BC, 234
 LeRoy EC, 567, 571, 576
 Lessell S, 1
 Levine PH, 137
 Levitin PM, 210
 Levy J, 62, 391
 Lewis AJ, 441
 Ley J, 461
 Lian JB, 573
 Liang G, 587
 Liebling MR, 574
 Lightfoot RW, 889
 Ligler FS, 551
 Linder E, 904
 Linn JE, 645
 Lint TF, 28
 Lippiello L, 909
 Lipton M, 583
 Little HA, 844
 Litwin A, 565
 Liu YK, 731
 Liyanage IS, 998
 Liyanage SP, 998
 Llorente L, 493
 Lockshin M, 600
 Loggie JM, 565
 Lorber A, 785
 Lospalluto J, 310
 Louie JS, 51, 539, 547, 582, 834
 Lourdes JM, 148
 Lowenstein MB, 58, 992
 Lowther DA, 675

Lubeck MJ, 839
Lyons H, 556

M

MacFarlane J, 575
Machtey I, 283
Mackenzie AH, 576
Madura J, 605
Magilavy DB, 554
Mainardi CL, 137
Major JC, 704
Makarova O, 45
Makue D, 210
Malawista SE, 564, 735
Mandel N, 613
Mandell B, 594
Mankin HJ, 761, 909
Manku MS, 492
Mann DL, 580, 586
Mannik N, 330, 555, 581
Maricq HR, 173, 576
Markenson JA, 266, 600
Martel W, 161, 739
Martin WJ, 880
Masi AT, 473, 480, 575, 576, 577
Massias P, 996
Matsuta K, 588
Matulis AA, 120
McCain GA, 574
McCarty DJ, 563, 723
McConkey B, 491
McCombs C, 578
McCord WC, 834
McDevitt HO, 690
McDuffie FC, 549
McGee JA, 575
McKinley P, 595
McLaughlin GE, 599
McLeod B, 567
McLeod RL, 306
McShane DJ, 576
Meachim G, 669
Mecker T, 562
Medsger TA, 576
Meenan RF, 827
Mehta J, 196, 594
Meigel WN, 418
Meisel AD, 553
Mellors JW, 577
Mellors RC, 577
Mendes NF, 326
Menzel J, 243
Mergenhausen, SE, 571
Messner RP, 561
Metges PJ, 993
Michalski JP, 306, 337, 578, 584
Miettinen A, 904
Milgrom F, 634, 639
Miller C, 196
Miller ML, 681
Mintz G, 148, 578
Mitnick H, 918
Miyawaki S, 803

Moeschberger M, 596
Mond JJ, 551
Monteil MM, 652
Moore MF, 556
Moore TL, 114, 579, 767, 820, 930, 935
Morgan AR, 407, 552
Morgan GJ, 362
Morgan RO, 492
Morris AD, 596
Moskowitz N, 210
Moskowitz RW, 166, 560, 579, 586, 987
Moss S, 597
Moutsopoulos HM, 551, 580, 798
M'Selfar A, 585
Mueller MN, 581
Müller-Eberhard HJ, 177, 567
Muniz O, 579, 597
Murphy WA, 367
Murray GC, 652
Musatti C, 326
Myers AR, 589, 978

N

Nahir M, 391
Namey TC, 399
Nardella FA, 581
Nassonova VA, 23
Nelson AM, 145, 715
Nelson RS, 572
Nelson JS, 983
Netter P, 997
Nies KM, 51, 539, 547, 582, 834
Nimni ME, 551
Nishimaki T, 634, 639
Norman CS, 539
Norman DA, 811
Noronha A, 598

O

O'Brien WM, 398
Ofuji T, 803
Oh JH, 72
Ohno O, 81, 516
Opelz G, 337
Osterland CK, 72
Ottaway JM, 441
Oxenhandler RW, 593

P

Pachman L, 604
Paget SA, 249, 558, 582
Palmoski M, 583, 942
Panush RS, 172
Parcianny RK, 572
Partamian L, 611
Passas C, 168
Patarroyo M, 558
Pattin S, 993
Patty JG Jr, 171, 284
Patzakis MJ, 401
Paulus HE, 62
Paxon CS, 592
Pearson CM, 170, 604

Pek S, 550
Pepper BJ, 97
Perez HD, 583
Perlish JS, 418
Perlman SG, 271
Perricone E, 453
Persellin RH, 316, 652
Pesce M, 129
Peter A, 785
Peters CJ, 767
Peters RS, 573
Petty DA, 587
Phillips PE, 249, 266, 582, 584, 880
Pigg JS, 286
Pinals RS, 285, 727
Pinching AJ, 597
Pincus T, 553, 873
Pisko E, 595
Pita JC, 579
Pittsley RA, 584
Plotz PH, 563, 570
Poole AR, 556
Pope C, 569, 792
Postlethwaite AE, 584
Pourel J, 997
Price TH, 504
Pritchard KI, 554, 585
Pruzanski W, 171

R

Raffoux C, 997
Rakic M, 397, 989
Ralph ED, 574
Ramcharan S, 690
Reeves JP, 204
Reginato AJ, 585
Reinecke RD, 588
Reinertsen JL, 204, 383, 586
Resnick D, 1, 395, 999
Reynolds MD, 377
Reynolds P, 544
Reza M, 604, 774, 972
Rich K, 603
Richards AJ, 280, 865
Riggs BL, 715
Rightsel WA, 575
Rimon D, 283
Riskin W, 282
Rivero SJ, 295, 493
Robbins DL, 114, 820
Roberts JL, 28
Roberts N, 557
Robertson JS, 595
Robinson D, 909
Robinson MF, 567
Robles E, 578
Robles-Saavedra EJ, 148
Roder JC, 545
Rodey GE, 889
Rodnan GP, 576
Rogoff JB, 865
Rose JE, 114
Rosenthal CJ, 699
Rosner IA, 586
Ross GL, 281
Rothfield N, 602
Roubinian J, 589

Royer GL, 572
Roztropowicz-Denisiewicz K, 699
Rubin RL, 587, 950
Ruddy S, 549
Russell AS, 407, 552
Ryan LM, 587, 889
Rynes RI, 588

S

Sakane T, 657
Samuelson CO, 681
Sandy JD, 675
Sanford KG, 863
Santer VB, 675
Santoli D, 553
Santos L, 326
Sapag-Hagar M, 447
Sapolsky AI, 588
Saurino BC, 183
Sauter S, 549
Sawada S, 589
Sawaya J, 611
Saxon A, 582
Scarola JA, 589
Schaller JG, 599
Scharf J, 391
Schechter SL, 864
Scheinberg MA, 326
Schimmer BM, 589, 740
Schlesinger M, 37
Schlumpf U, 280
Schrohenloher RE, 562
Schumacher HR, 353, 429, 513, 585, 590, 597
Schwabe AD, 573
Scopelitis E, 590
Scott JT, 742
Scott ME, 550
Segond P, 996
Seleznick M, 37
Sergeant JS, 192, 343
Seyer JM, 584
Shainhouse Z, 554
Shapiro RF, 1, 599
Sharp, GC, 576, 593, 604
Sharp, JT, 169
Sharrow SO, 551
Shepard JD, 591
Sheps S, 549
Siegel RC, 591
Silverman M, 554, 592, 595, 839
Silverman SL, 592
Simkin PA, 592
Simon T, 785
Singhal SK, 545
Singsen BH, 401, 593
Skilton JC, 864
Skinner M, 153
Skosey JL, 598, 995
Slaughter L, 593
Slusser D, 210
Smith CA, 559
Smith CB, 97
Smith WE, 441
Smolen J, 243

Smythe HA, 539
 Snyder SM, 306
 Sobol N, 393
 Sokoloff L, 754
 Solomon SD, 279
 Southard GL, 133
 Spagnola AM, 467, 564
 Spieler PN, 564
 Spilberg I, 594
 Spitz JR, 540
 Sponzilli EE, 690
 Stahl NI, 594, 665
 Stankaitiene DJ, 120
 Starkebaum G, 504
 Steere AC, 564
 Steffen C, 243
 Steigerwald JC, 592, 595
 Steinberg AD, 204, 414, 570, 586, 657, 798, 873
 Stevens MB, 589, 606
 Stevens R, 582
 Stockman A, 742
 Streiff F, 997
 Struth AG, 595
 Stuard ID, 975
 Sturgeon JFG, 585
 Sullins D, 596
 Sun NC, 547
 Sundsmo JS, 177

T

Tabatabai MR, 596
 Talal N, 23, 306, 337, 578, 584, 589, 853

Tan EM, 542, 556
 Taplits MS, 596
 Tateishi H, 81
 Taylor G, 792
 Taylor-Robinson D, 569, 792
 Teitelbaum SL, 367
 Templin DW, 224
 Tenenbaum J, 554, 597
 Teresaki PI, 337, 467
 Thomson ABR, 234
 Travers RL, 597
 Trenholm GM, 572
 Turner R, 595

U

Uberoi S, 598
 Ugai K, 598
 Urman JD, 58
 Urowitz MB, 539, 559
 Utsinger PD, 210, 599

V

Valentine TV, 599
 van der Rest M, 556
 van de Sande JH, 591
 Vansant J, 192
 Vasey FB, 72
 Vater CA, 591
 Vaughan JH, 114, 567, 593, 767, 820
 Vazquez T, 613
 Venge P, 107
 Verity MA, 547
 Vigliani G, 761

Vignos PJ Jr, 391
 Vitetta ES, 551
 Volankis JE, 562

W

Walker SE, 599, 709
 Wallace C, 599
 Wallace SL, 862, 958
 Warburg M, 600
 Ward JR, 681, 968
 Wasner C, 600, 601
 Waison JJ, 591
 Waytz PM, 601
 Wedgwood R, 599
 Weinberger A, 740
 Weiner M, 37
 Weinstein A, 58, 168, 585, 602
 Weiss TD, 579, 935
 Weissman G, 278, 918
 Werb Z, 137
 White BS, 539
 Whitten ED, 557
 Whyte MP, 367
 Wiesner KB, 1, 599
 Wilcox S, 785
 Wiletski C, 694
 Wilkinson R, 72
 Willans M, 183
 Williams GW, 204
 Williams RC Jr, 23
 Wilske KR, 565
 Wilson CH Jr, 617
 Wilson WF, 592
 Winchester RJ, 558

Winfield JB, 17, 289
 Witorsch P, 271
 Woessner JF, 588
 Wohlgethan JR, 603
 Wolf RE, 238
 Wolfe F, 576
 Wolfe JF, 593, 604
 Wood A, 461
 Woolsey RL, 192
 Woolsey RM, 983
 Worthington JW, 548
 Wortmann RL, 603
 Wright V, 619

Y

Yamamoto K, 909
 Yaron I, 604, 694
 Yaron M, 604, 608, 694
 Yatts P, 595
 Yelin EH, 827
 Yeni P, 996
 Young AL, 133
 Young-Rodenchuck M, 568
 Yount WJ, 210, 549
 Yunus M, 167

Z

Zapanta M, 605
 Zein N, 605
 Zeitz H, 28
 Ziff M, 310, 547, 551, 598
 Zizic TM, 589, 606
 Zor U, 604, 694
 Zuckner J, 579, 930, 935, 983
 Zurier RB, 571
 Zvaifler NJ, 546

SUBJECT INDEX

Arthritis and Rheumatism, Volume 21, Numbers 1 through 8, 1978

Page numbers in italics refer to papers presented at the 42nd Annual Scientific Session of the American Rheumatism Association, May 31-June 2, 1978. The Proceedings of the Conference on New Directions for Research in Systemic Lupus Erythematosus and The Twenty-Third Rheumatism Review are indexed separately.

A

- ACC. *see* Articular chondrocalcinosis
- Acetylation phenotypes
distribution of in systemic lupus erythematosus, 192-195
renal disease and, 194
- Acromegaly, carpal tunnel syndrome and, 221
- ACT. *see* Articular collagenous tissues
- Active urinary sediment, effect on infection in systemic lupus erythematosus, 42
- Acute hematogenous osteomyelitis, septic synovitis and, 968-971
in adults, 968
in children, 968
pyarthrosis and, 968-971
- Acute rheumatic fever, *see* Rheumatic fever, acute
- ADCC. *see* Antibody-dependent cell-mediated cytotoxicity
- Adjuvant arthritis
aspirin as treatment for, 256
platelet aggregates in, 256-259
in rats, 169-170, 256-259
thrombocytosis and, 256-259
virazole effect on, 568
- Agammaglobulinemia, immunodeficiency in, 554
- Ammonium sulfate assay, reevaluation of, 950-957
- Amyloid arthritis, multiple myeloma and, 148
- Amyloid arthropathy
chondrocalcinosis and, 587-588
dysproteinemia and, 587-588
- Amyloidosis
carpal tunnel syndrome and, 221, 223
chemical nature of, 153-156
genesis of, 156-158
investigation of, current trends, 153-160
in juvenile rheumatoid arthritis, 699-703, 867-868
pathogenetic pathways in development of, 158
- ANA. *see* Antinuclear antibodies
- Ankylosing vertebral hyperostosis. *see* Forestier's disease
- Ankylosing spondylitis
in American blacks, 528-530
buttressing of femoral neck in, 161-162
in children, 401-406
diagnostic criteria of, 383
HLA antigens and
HLA-B7 and, 528-530
HLA-B27 and, 337, 383, 528-530, 885
HLA-C locus antigens in, 886
HLA-DRw and, 997
rheumatoid arthritis and, 383-389
rheumatoid vasculitis and, 383-389
Sjögren's syndrome and, 383-389
spinal pseudoarthrosis in, 485-490
subgroup of, 528-530
total hip replacement in, 401-406
- Anti-DNA antibodies
ammonium sulfate assay for, 950-957
central nervous disease and, 289-294
detection of, 390-391
immunochemical characteristics of, 543
peripheral blood lymphocyte synthesis of, 582
in systemic lupus erythematosus, 289-294, 543, 582, 602, 950
spontaneous responses in autoimmune mice, 545
- Anti-DNA complexes, in systemic lupus erythematosus, 17-22, 24-25
- Anti-antibody inhibition test, 639, 641, 642
- Antibody-dependent cell-mediated cytotoxicity
assay reproducibility of, 100
rheumatoid synovial cells susceptibility to, 97-105
time course of, 101
- Antiepitheial antibodies, in Yersinia infection, 904-908
- Antigen
fate of after injection in rabbits, 918-929
HLA. *see* HLA antigens
- Antiimmunoglobulins
in osteoarthritis, 120-128
properties of, 120-128
in rheumatoid arthritis, 120-128
reactive with human and rabbit IgG, 120-128
in rheumatic fever, 120-128
- Antilymphocyte antibodies
central nervous system disease and, 289-294
in systemic lupus erythematosus, 23-27, 289-294
- Antinuclear antibodies (ANA)
in rheumatoid arthritis, 645-651
rheumatoid factor and, 645-651
- Antipolynucleotide antibodies, in systemic lupus erythematosus, 23-27
- Antiviral antibodies, in systemic lupus erythematosus, 23-27
- ARA Preliminary Criteria for classification of systemic lupus erythematosus, suggested revision of, 602
- Arteritis
declassification of, 171
giant cell, 365, 391-393
non-giant cell temporal, 362-366
temporal, 362-366
- Arthritis. *see also* Rheumatic diseases, Rheumatoid arthritis
adjuvant. *see* Adjuvant arthritis
amyloid, 148
antigen-induced, 675-680
axial psoriatic, 74
cartilage matrix components, effects on, 677-678
in children, 401-406
Danazol and, 493-494
ferritin-induced, 81-91
gonococcal. *see* Gonococcal arthritis
hemophilic. *see* Hemophilia
HLA-B27 and, 542, 995-998
HLA-C and, 542, 885-888
infectious agent associations with, 575
inherited deficiency of fifth component in, 792-797

as intestinal bypass postsurgical complication, 599, 605
 juvenile rheumatoid, *see* Juvenile rheumatoid arthritis
 Lyme, *see* Lyme arthritis
 mycoplasma pulmonis induced, 792-797
 myeloma, 148
 peripheral psoriatic, 72-76
 proteoglycan, effects on, 675-680
 psoriatic, *see* Psoriatic arthritis
 rheumatoid, *see* Rheumatoid arthritis
 satellite clinic, 727-730
 septic, 150
 severity, numerical measure of, 348-352
 sulfanilamidoindazole, 681-689
 Tc-pertechnetate uptake in, 348-352
 traumatic, 76-80
 zinc and penicillamine therapy combined in, 492
 Arthritis-dermatitis syndrome, as intestinal bypass postsurgical complication, 599
 Arthropathy
 congenital flexion contractures of fingers in, 429-437
 cutaneous polyarteritis and, 281-282
 familial, 429-437
 idiopathic Charcot, *see* Idiopathic Charcot arthropathy
 inflammatory and noninflammatory, 461-466
 juvenile rheumatoid arthritis contrasted to, 433
 pathologic features of, 429-437
 synovial cell growth in, 461-466
 Articular cartilage
 collagenase activity, 761-766
 horizontal splitting in patellar, 669-674
 in inflammatory arthritis, 909
 osteoarthritis and, 761-766
 prostaglandins and, 909-917
 proteoglycan content and synthesis in, 675-680
 rheumatoid arthritis and, 909
 Articular chondrocalcinosis, 447-452
 Articular collagenous tissues
 changes in, 83-86
 in ferritin-induced arthritis, 81-91
 immunoglobulin aggregates interactions with, 516-527
 immunologically induced changes in, 86
 Aseptic necrosis, thalassemia and, 280
 Aspirin, *see also* Salicylates
 for adjuvant arthritis, 256
 for migrainous phenomena, 14
 Atypical axial osteomalacia, 715-722
 ankylosing spondylitis and, 715-722
 treatment for, 722
 vitamin D and, 715, 722
 Autoimmune anemia, mixed connective tissue disease and, 995-997
 Autoimmune neutropenia, *see* Neutropenia
 Autoimmunity, 853-862
 autoimmune disease and, 856-858
 Nafoxidine effect on, 414-417
 self-recognition and, 854-856
 sex hormones and, 414-417
 Azathioprine
 and polymyositis, 548
 and rheumatoid arthritis, 539
 and systemic lupus erythematosus, 39-40, 570

B

Back pain, transaxial tomography in assessment of, 541-542
 Behcet's syndrome, clinical associations with, 623-624, 626

Benign rheumatoid nodules (BRN), rheumatoid factor in children with, 930-934
 Betamethasone for flexor tenosynovitis, 94
 Bone marrow transplantation, skin changes following, 557
 Bony ankylosis, rheumatoid arthritis diffuse idiopathic skeletal hyperostosis and, 4
 Bony sclerosis, rheumatoid arthritis diffuse idiopathic skeletal hyperostosis and, 4
 BRN, *see* Benign rheumatoid nodules
 Bursitis
 hemochromatosis and, 844-848
 rheumatoid arthritis secondary to, 147-149
 subacromial, 147-149
 Buttredding of femoral neck, 161-164
 in ankylosing spondylitis, 161-162
 cause of, 161-162
 diagnostic value of, 161-164
 in ischemic necrosis, 161-162
 in osteoarthritis, 161-163
 in rheumatoid arthritis, 161-163

C

C-reactive protein
 in rheumatoid arthritis, 491
 in systemic lupus erythematosus, 605
 C2 deficiency (C2D)
 antinuclear antibodies in, 28
 complement activity in serum in, 30
 dermatitis in, 28
 family studies in, 30
 with fulminant lupus erythematosus, 28-36
 joint involvement in, 28
 nephritis and, 28-35
 photosensitivity in, 28
 protein levels and, 31
 renal involvement in, 28
 in systemic lupus erythematosus, 28-35
 C2D, *see* C2 deficiency
 C3 serum, level in systemic lupus erythematosus, 602
 C4, metabolism of in rheumatoid arthritis, 567-568
 Calcium ionophore, lymphocyte response to, 326-329
 rheumatoid arthritis and, 326-329
 systemic lupus erythematosus and, 326-329
 Calcium pyrophosphate dihydrate crystals, 447-452
 Capillary microscopy for clinicians, 173
 Carboxyglutamate, vitamin K dependent synthesis of, 573-574
 Carpal and tarsal multicentric osteolysis, *see* Idiopathic multicentric osteolysis
 Carpal tunnel syndrome
 acromegaly and, 221
 age distribution of patients with, 223
 amyloidosis and, 221, 223
 cause of, 223
 Danazol and, 493-494
 definition of, 221
 diabetes and, 221
 electrical studies in, 865
 gout and, 221
 myxedema and, 221, 223
 polymyalgia rheumatica and, 221-223, 865
 rheumatoid arthritis and, 221-223
 sex distribution of patients with, 223
 steroid therapy in, 223
 tenosynovitis as cause of, 223
 Cell-mediated cytotoxicity, in rheumatoid arthritis, 601-602
 Central nervous system disease

- anti-DNA antibodies in, 289-294
 - anti-Sm in, 293
 - antilymphocyte antibodies in, 289-294
 - serologic studies in, 289-294
 - serum hemolytic complement activity in, 289
 - systemic lupus erythematosus and, 289-294
 - Central retinal vein occlusion, in systemic lupus erythematosus, 839-843
 - Cervical disc disease, origin of in rheumatoid arthritis, 737-739
 - Chondrocalcinosis
 - amyloid arthropathy and, 587-588
 - articular, 447-452
 - cartilage phosphatases in, 597
 - as cause of arthritis, 174
 - Chrysotherapy, *see also* Gold compounds
 - in cryoglobulinemia, 790
 - efficacy of, 513-515
 - in extrinsic bronchial asthma, 790
 - immunoglobulin synthesis and, 785-791
 - immunosuppressive effect of, 785
 - in macroglobulinemia, 790
 - nitritoid reaction in, 868-869
 - ocular chrysiasis after, 704-708
 - ophthalmologic complications of, 704-708
 - in pemphigus, 790
 - postinjection site pain syndrome in, 868-869
 - in psoriatic arthritis, 513-515
 - in rheumatoid arthritis, 513-515, 785-791
 - rheumatoid factor and, 785-791
 - in Sjögren's syndrome, 790
 - toxicity of, 513-515
 - CIC, *see* Immune complexes
 - Circulating immune complexes, *see* Immune complexes
 - Clq-sepharose eluates, characterization of, 20
 - CNS disease, *see* Central nervous system disease
 - Colchicine, 731-736
 - excess dosage effects, 733, 735-736
 - gout, as treatment for, 731, 736
 - marrow aplasia induced by, 731-736
 - Collagen
 - biosynthesis during repair of articular cartilage, 551
 - production of by multinucleated cell cultures, 745-753
 - Complement components, *see also* C2 deficiency, C3 serum, C4
 - familial deficiency of subunits of first, 958-967
 - fifth, inherited deficiency of in arthritis, 792-797
 - Complement pathways
 - alternative in nephritis, 28-35
 - properdin, 30-32
 - CON-A, *see* Concanavalin-A
 - Concanavalin-A (CON A)
 - levamisole and, 326-329
 - lymphocyte response to, 326-329
 - rheumatoid arthritis and, 326-329
 - systemic lupus erythematosus and, 326-329
 - Connective tissue disease, *see also* Mixed connective tissue disease
 - nuclear antigens and, 803-810
 - Corticosteroids
 - antiphlogistic effect in paraarticular disorders, 94
 - bacterial infections, relation to, 112
 - for giant cell arteritis, 365
 - intra-tendon sheath, 92-96
 - in osteoarthritis, 556
 - in polyarthritis, 365
 - in rheumatoid arthritis, 92, 96, 110-112
 - associated with tenosynovitis, 92-96
 - in systemic lupus erythematosus, effects on infection, 39, 44
 - Costs of rheumatoid arthritis, 827-833
 - income losses, 830-832
 - medical, 829-830, 832
 - psychosocial, 832-833
 - CPPD crystals, *see* Calcium pyrophosphate dihydrate crystals
 - Crohn's disease
 - bone scanning an, 235
 - clinical abnormalities in, 235
 - clinical associations with, 623, 625-626
 - epidemiologic studies in, 628-629
 - HLA-B27 and, 235-236
 - nonenteric manifestations of, 234
 - psoriasis and, 236
 - quantitative sacroiliac scintigraphy in, 234-237
 - radiologic abnormalities in, 235
 - Reiter's syndrome and, 236
 - sacroiliitis and, 234
 - CRVO, *see* Central retinal vein occlusion
 - Cryoglobulinemia, chrysotherapy in, 790
 - Cyclophosphamide for lupus nephritis, 570
- ## D
- D-penicillamine
 - breast gigantism with, 167-168
 - and rheumatoid arthritis, 110-112, 396
 - Danazol and arthritis, 493-494
 - Degenerative joint disease, synovial fluid lubricating ability in, 754-760
 - Dermatomyositis, nuclear antigens and, 804
 - Diabetes, carpal tunnel syndrome and, 221
 - Diffuse idiopathic skeletal hyperostosis, (DISH), 1-6
 - Diffuse proliferative glomerulonephritis, in systemic lupus erythematosus, 577-578
 - Diphosphonates, effects of in articular cartilage, 942-949
 - DISH, *see* Diffuse idiopathic skeletal hyperostosis
 - Disappearing carpal bones, *see* Idiopathic multicentric osteolysis
 - DJD, *see* Primary degenerative joint disease
 - DNA binding, in systemic lupus erythematosus, 552
 - DNA complexes, in systemic lupus erythematosus, 17-22
 - DNA structure
 - analysis of, 407-413
 - ethidium bromide in analysis of, 407-413
 - hydroxyapatite chromatography in analysis of, 407-413
 - DNA-protein, rheumatoid factor and, 540
 - DNA/Anti-DNA complexes
 - in systemic lupus erythematosus, 17-22
 - sunburn and, 21
 - trauma and, 21
 - DPGN, *see* Diffuse proliferative glomerulonephritis
 - Dysproteinemia, amyloid arthropathy in absence of, 587-588
- ## E
- Echovirus-associated polyarthritis, 978-981
 - Ehlers-Danlos syndrome, 545
 - Estrogen
 - and systemic lupus erythematosus, 306
 - and rheumatoid arthritis, 506-561
 - Experimental ferritin-induced arthritis, *see* Ferritin-induced arthritis
 - Extrinsic bronchial asthma, chrysotherapy in, 790
- ## F
- Factor B and rheumatoid arthritis, 567-568
 - Familial Mediterranean fever in children
 - diagnosis of, 573
 - treatment of, 573

Familial arthropathy, 429-437
see also Arthropathy

Familial lupus, 183-191
see also Systemic lupus erythematosus

Felty's syndrome
 immune complexes in, 310-315
 immunodiffusion studies in, 311-312
 inhibition of marrow-granulocyte precursors in, 560
 leukopenia and, 310
 rheumatoid arthritis, comparison to, 310-315
 ultracentrifugation studies in, 312-313

Femoral neck, buttressing of, 161-164, 869

Ferritin-induced arthritis
 articular collagenous tissue changes in, 81-91
 chronic inflammation in, 81-91
 immunization protocol influence on severity of, 83
 rheumatoid disease resemblance to, 90

Fibrinogen
 half-life of, 334-345
 heparin and, 345
 systemic lupus erythematosus and, 343
 turnover in progressive systemic sclerosis, 343-347

Fingers, congenital flexion contractures of, 429-437

Flexor tenosynovitis
 betamethasone treatment for, 94
 corticosteroid treatment for, 92-96
 natural history of, 95
 nonsurgical management of, 92-96
 prednisolone treatment for, 94
 in rheumatoid arthritis, 92-96
 surgical management of, 92
 triamcinolone treatment for, 94

FLMP, *see* Formylmethionyl-leucyl-phenylalanine

FME, *see* Familial Mediterranean fever

Forestier's disease (ankylosing vertebral hyperostosis)
 etiology of, 468
 HLA antigens in, 467-472
 HLA-B27 and, 468-471
 origin of, 467
 in Pima Indians, 467-472
 race distribution in, 471
 radiographic characteristics of, 467

Formylmethionyl-leucyl-phenylalanine, methyl ester of, 133-136

Frentizole, in systemic lupus erythematosus, 599

FS, *see* Felty's syndrome

FT, *see* Flexor tenosynovitis

Fulminant lupus erythematosus, C2 deficiency with, 28-35

G

Gastric mucosa, therapy for, 572

Giant cell arteritis
 in blacks, 863
 blind proximal temporal artery biopsy in, 780-784
 corticosteroid therapy in, 365
 diagnosis of, 780-784
 occult, 565
 polymyalgia rheumatica and, 780
 race distribution in, 391-393
 temporal arteriography in, 780-784

Glomerulonephritis
 in polymyositis, 554
 sicca syndrome and, 580

Glycosaminoglycan synthesis, effect of diphosphonate on, 942-949

Gold, *see* Chrysotherapy, Gold compounds

Gold compounds

distribution in guinea pig serum, 441-446
 dosage schedules of, 168-169
 efficacy of, 513-515
 inhibition of, 133-136
 levels in guinea pig serum, 441-446
 monocytes and, 133-136
 orally administered, 441-446
 in psoriatic arthritis, 513-515
 reactions to, 281
 in rheumatoid arthritis, 513-515
 toxicity of, 513-515

Gold salts, *see* Gold compounds

Gonococcal arthritis, diagnosis of, 572-573

Gout
 carpal tunnel syndrome and, 221
 colchicine treatment for, 731
 multiple myeloma and, 150
 polyarticular attacks and, 544
 rheumatoid factor in, 544, 741-742
 synovitis and, 544

H

Hand
 primary degenerative joint disease of, 210-211, 215, 218
 Kruskal-Wallis test for task differences with right and left, 214
 pain in early diagnosis of lepra, 282-283
 right and left differences, 218
 structure and function of in industrial settings, 210-220

Hemarthrosis
 anticoagulant therapy as cause of, 151
 heparin relationship with, 740
 in myeloma arthritis, 148-151
 sodium warfarin relationship with, 740

Hemochromatosis, *see* Hemochromatotic arthropathy

Hemochromatotic arthropathy
 mimicking rheumatoid arthritis, 844-848
 phlebotomy as treatment for, 844, 848

Hemophilia
 biochemical characteristics of, 141-142
 clinical characteristics of, 137
 proliferative synovitis in, 137-144
 synovitis in, 137-144

Herpes zoster
 clinical manifestations of, 799-800
 in systemic lupus erythematosus, 798-802
 systemic lupus erythematosus activity and, 800
 treatment of systemic lupus erythematosus and, 800

Histocompatibility antigens, *see* HLA Antigens

Hip diseases, buttressing of femoral neck in, 161-164

HLA antigens
 in ankylosing spondylitis, *see* Ankylosing spondylitis, HLA antigens
 and
 in arthritis, 542, 885-888, 995-998
 in black Americans, 892-894
 and peripheral psoriatic arthritis, 72-76
 in psoriasis vulgaris, 73
 in spondylarthritis, 889-895
 in systemic lupus erythematosus, 183-191

HLA-B7, ankylosing spondylitis associated with, 528-530

HLA-B8, rheumatoid arthritis and, 338

HLA-B27
 ankylosing spondylitis and, 337, 528-530, 885
 arthritis and, 542
 associated arthritis, 885-888
 in Crohn's disease, 235-236
 Forestier's disease and, 467-472

HLA-C locus antigens, 885-888
 in idiopathic ankylosing spondylitis, 889
 inflammatory bowel disease and, 236
 myasthenia gravis and, 337
 race distribution and, 528
 in Reiter's syndrome, 885, 889
 in spondylarthritis, 889-895
 HLA-BW38, peripheral psoriatic arthritis and, 72-75
 HLA-C, arthritis and, 542
 HLA-Cw1, in spondylarthritis, 889-895
 HLA-Cw2, in spondylarthritis, 889-895
 HLA-Dw3, rheumatoid arthritis and, 338
 HLA-Dw4, and ankylosing spondylitis, 997
 Homozygous C2 deficiency, with fulminant lupus erythematosus, 28-36
 Horseradish peroxidase
 extravascular localization of, 923-925
 injection into rabbits, 918-929
 ultrastructural cytochemistry after injections of, 921-925
 Hyaluronate, prostaglandin E and the production of, 694-698
 Hydralazine and systemic lupus erythematosus, 565-566
 Hydroxychloroquine
 for migrainous phenomena, 14
 ophthalmologic safety of long-term use of, 588

I

IC, *see* Immune complexes
 Identical twins, *see* Monozygotic twins
 Idiopathic ankylosing spondylitis, HLA-B27 and, 889
 Idiopathic Charcot arthropathy, 723-728
 Idiopathic multicentric osteolysis
 age of onset, 367
 genetic predisposition to, 367
 histopathology of, 372
 nephropathy and, 372
 origin of name of, 367
 trauma, relationship to, 367
 Immune complexes, *see also* DNA/Anti-DNA complexes
 anti-antibody inhibition test for soluble, 639, 641-642
 Lyme arthritis and, 564
 in mixed connective tissue disease, 562-563
 monocyte cytotoxicity and, 543-544
 polymorphonuclear leukocytes, interaction with, 598
 in rheumatoid arthritis, 107, 639-644
 in sicca syndrome, 580
 in systemic lupus erythematosus, 107, 539-540
 Immune renal disease, 549
 Immune synovitis, oophorectomy in, 560-561
 Immunoglobulin
 measurement of, 331-334
 on MSU crystals, 353-361
 in tophi, 353-361
 Immunoglobulin aggregates, 516-527
 Immunoglobulin synthesis, impaired by PBL, 51-57
 Immunologic network, 853-862
 chronic idiopathic disease and, 859
 Immunology, 853-862
 history of, 853-854
 IMO, *see* Idiopathic multicentric osteolysis
 Inflammatory bowel disease, HLA-B27 and, 236
 Informed consent, validity of, 991-992
 Intestinal bypass
 arthritis after, 599, 605
 postsurgical complications of, 599
 Intratendon sheath corticosteroid treatment, 92-96
 Ischemic necrosis

buttressing of femoral neck in, 161-162
 management of, 606
 in systemic lupus erythematosus, 606

J

Joint inflammation, relationship to immunologically induced changes in ACT, 86
 JRA, *see* Juvenile rheumatoid arthritis
 Juvenile rheumatoid arthritis (JRA)
 adoption frequency among patients with, 231-232
 age at onset of, 230
 American and European, contrast of, 699-703
 amyloidosis of, 699-703, 867-868
 causes of, 229-233
 clinical management of, 129-132
 corticosteroid therapy in, 131
 etiology of, 229
 familial arthropathy contrasted with, 433
 fingerstick method for measurement of plasma salicylate in, 129-132
 genetic predisposition to, 229
 hand in, 561-562
 parents' marital status of patients with, 231, 233
 psychosocial factors in, 229-233
 rheumatoid arthritis distinguished from, 231
 rheumatoid factor in, 579
 SAA protein levels in, 699-703
 salicylate and, 129-132
 stress factors and, 232
 surgical management of, 401-406
 total hip replacement in, 401-406

K

Klinefelter's syndrome
 monozygotic twins with, 306-309
 myasthenia gravis and, 306-309
 systemic lupus erythematosus and, 306-309
 Knee
 diagnostic arthroscopy of, 541
 osteoarthritis of, 556
 radiographic survey of, 395-396
 Knee joint, Tc-pertechnetate uptake in, 348, 352
 Kruskal-Wallis test, 214

L

Lactic acid, of synovial fluid, 774-779
 Latex fixation rheumatoid factor test, 224, 226
 Legionnaires' disease, in patient with systemic lupus erythematosus, 975-977
 Leprosy, hand pain in early diagnosis of, 282-283
 Leukocyte functions
 estradiol effects on, 324
 pregnancy serum effects on, 316-325
 Leukopenia
 colchicine as cause of, 733
 of Felty's syndrome, 310
 in systemic lupus erythematosus, 504
 Levamisole, in rheumatoid arthritis, 326-329, 589-590
 Lupus, familial, 183-191
see also Systemic lupus erythematosus
 Lupus nephritis, 21
 azathioprine in, 570

cyclophosphamide in, 570
 in systemic lupus erythematosus, 41, 43
 Lyme arthritis
 immune complexes and, 564
 juvenile rheumatoid arthritis contrasted with, 167
 Lymphocyte count
 disease activity, relationship with, 300
 lymphopenia and, 297-299
 Lymphocytes
 B in NZB mice, 551
 monocyte cytotoxicity and, 543-544
 rosette formation and propranolol, 767-774
 scleroderma and, 423
 Lymphocytotoxic antibodies, in systemic lupus erythematosus, 189-190
 Lymphoma, in Sjögren's syndrome, 585
 Lymphopenia
 diagnostic significance of, 301
 lymphocyte count and, 297-299
 prognostic significance of, 301-303
 in systemic lupus erythematosus, 295-305

M

Macroglobulinemia, chrysotherapy in, 790
 Marrow aplasia, colchicine-induced, 731-736
 MCTD, *see* Mixed connective tissue disease
 Membrane attack complex, 177-182
 polymorphonuclear leukocytes and, 180
 in systemic lupus erythematosus, 179
 Migrainous phenomena
 description of, 8-9
 electroencephalograph of patients with, 12-13
 fortification specters in, 8-9
 scotomas in, 9
 in systemic lupus erythematosus, 7-16
 spinal fluid analysis of patients with, 12-13
 treatment for, 13-14
 aspirin, 14
 hydroxychloroquin, 14
 prednisone, 14
 visual hallucinations in, 7-9
 Mitogens, cell response to in NZ mice, 199-200
 Mixed connective tissue disease (MCTD), 497-503
 arthritis of, 497-503
 autoimmune anemia in, 995-997
 circulating immune complexes in, 562-563
 clinical features of, 497-503
 gastrointestinal systemic sclerosis in, 811-819
 genetic predisposition to, 709-714
 histologic evaluation of, 593
 history of, 811
 myelitis in, 982-986
 neurologic involvement in, 982-986
 pattern of disease presentation, 498
 prognosis of, 985
 rheumatoid arthritis and, 497-498, 502
 serologic description of, 982
 in siblings, 709-714
 systemic sclerosis in, 811-819
 thrombopenia in, 995-997
 transverse myelitis in, 982-986
 Mixed cryoglobulinemia, synovial fluid in, 740-741
 Mixed tissue disease, *see* Mixed connective tissue disease
 MNC, *see* Monocytes
 MON, *see* Multicentric osteolysis with nephropathy

Monocyte cytotoxicity, effect of immune complex on, 543-544
 Monocytes
 gold compound inhibition and, 133-136
 PMN and, 133-136
 Monosodium urate crystals
 agglutination of, 354, 356-360
 cellular interaction with, 558, 896-903
 immunoglobulin on, 353-361
 Monozygotic twins
 discordant for myasthenia gravis, 306-309
 discordant for systemic lupus erythematosus, 306-309
 Klinefelter's syndrome in, 306-309
 MSU crystals, *see* Monosodium urate crystals
 Multicentric osteolysis with nephropathy, 372, 375
 Multiple myeloma
 amyloid arthritis and, 148
 gout and, 150
 rheumatic manifestations of, 149
 septic arthritis and, 150
 Muscle disease
 in polymyositis/dermatomyositis, 62-71
 in progressive systemic sclerosis, 62-71
 Myasthenia gravis
 HLA-B27 and, 337
 Klinefelter's syndrome and, 306-309
 monozygotic twins and, 306-309
 systemic lupus erythematosus and, 306-309
 thymus, role of, 492-493
 Myelitis, transverse in mixed connective tissue disease, 982-986
 Myeloma arthritis, hemarthrosis in, 148-151
 Myeloma
 rheumatoid arthritis and, 263
 systemic lupus erythematosus and, 260-265
 symptoms of, 262
 Myopathy
 complicated, 64, 66
 diagnostic considerations in, 62-71
 in scleroderma, 62-71
 simple, 64
 therapeutic considerations in, 64, 69-70
 Myxedema, carpal tunnel syndrome and, 221, 223

N

Nafoxidine, 414-417
 autoimmunity and, 414-417
 DNA antibodies and, 415
 New Zealand mice and, 414-417
 proteinuria and, 415
 Nephritis
 and alternative complement pathway, 28-35
 in systemic lupus erythematosus, 41, 43
 Nephropathy, in polymyositis, 554
 Neutral proteoglycanase, forms of, 588
 Neutropenia
 kinetics in, 507
 serum fractionation studies in, 508-510
 in systemic lupus erythematosus, 504-512
 New Zealand mice
 autoimmune diseases in, 51, 850
 cell effects of mitogens in, 199
 concanavalin, effects on, 204-209
 foreign antigens, response to, 200
 lymphocyte function, effect on, 196-203
 mitogens, response to, 199-200
 nafoxidine and, 414-417
 suppressor lymphocyte in aged, 578

therapeutic studies in, 204-209
 thymosin in, 196-203
 Nuclear antigens
 cellular localization of, 805-806
 clinical features of, 806-807
 connective tissue diseases and, 803-810
 dermatomyositis and, 804
 physicochemical properties of, 806
 sicca syndrome and, 810
 systemic lupus erythematosus and, 804
 NZB/NZW mice, *see* New Zealand mice

O

Oncornavirus C, *see* Type C virus
 Oophorectomy, in immune synovitis, 560-561
 Oral mucosal ulceration
 clinical features of, 58-60
 corticosteroid treatment for, 60
 hard palate involvement in, 59
 renal disease associated with, 59
 serologic features of, 58-59
 in systemic lupus erythematosus, 58-61
 Osteoarthritis
 articular cartilage collagenase activity and, 761-766
 buttressing of femoral neck in, 161-164, 869
 cartilage phosphatases in, 597
 corticosteroid therapy in, 556
 features of, 163-164
 Rumalon R as treatment for, 494-496
 sampling problems in, 763
 sex hormone effects in, 586-587
 synovial lubrication in, 758
 Osteomalacia
 atypical axial, 715-722
 causes of, 715
 Osteopenia, glucocorticoid-induced in rabbits, 581
 Osteophytes, rheumatoid arthritis diffuse idiopathic skeletal hyperostosis and, 4
 Osteoporosis
 of the knee, 992-993
 and rheumatoid arthritis diffuse idiopathic skeletal hyperostosis, 4

P

Pancytopenia, caused by colchicine, 735
 Paravertebral ossification, vertebral sarcoidosis with, 271-276
 Patellar articular cartilage, horizontal splitting in, 669-674
 Pemphigus, chrysotherapy in, 790
 Penicillamine therapy, *see* D-penicillamine
 Peptidoglycans, 534-537
 Pericarditis, corticosteroid therapy in, 391
 Peripheral blood leukocytes, in systemic lupus erythematosus, 177-182
 Peripheral blood lymphocytes
 anti-DNA synthesis by, 582
 calcium ionophore and, 326-329
 Con-A and, 326-329
 immunoglobulin synthesis impaired by, 51-57
 PHA and, 326-329
 in rheumatoid arthritis, 326-329, 593-594
 in systemic lupus erythematosus, 51-57, 326-329
 Peripheral blood neutrophils
 antiimmunoglobulin effects on, 598
 functional responses of, 598

PGC, *see* Proteoglycan aggregates
 PHA, *see* Phytohemagglutinin
 Phagocytosis, kinetic studies of, 107-113
 Phytohemagglutinin
 levamisole and, 326, 329
 lymphocyte response to, 326-329
 rheumatoid arthritis and, 326-329
 systemic lupus erythematosus and, 326-329
 Pima Indians, Forestier's disease and, 467-472
 Plasma salicylate, measurement of in juvenile rheumatoid arthritis, 129-132
 Platelets, in synovial space, 994-995
 PM/DM, *see* Scleroderma
 PMN leukocytes, *see* Polymorphonuclear leukocytes
 Pokeweed mitogen, as immunoglobulin inducer, 51-54
 Polyarthritis
 abdominal syndromes in, 606
 arthropathy associated with, 281-282
 corticosteroid therapy in, 365
 Polyarthritides
 echovirus-associated, 978-981
 gout and, 544
 seronegative, *see* Seronegative polyarthritides
 Polymorphonuclear (PMN) leukocytes
 chemotactic responses of, 133-136
 depletion in systemic lupus erythematosus, 504-512
 functions
 phagocytosis and, 316
 pregnancy serum effects on, 316-325
 immune complexes, interaction with, 598
 microtubule control of, 594
 phagocytic rates of, 109
 serum independent particle uptake by, 107-113
 Polymyalgia rheumatica, carpal tunnel syndrome and, 221-223, 865
 Polymyositis
 azathioprine treatment in, 548
 glomerulonephritis in, 554
 nephropathy in, 554
 Polymyositis/dermatomyositis, *see* Scleroderma
 Prednisolone
 for flexor tenosynovitis, 94
 for migrainous phenomena, 14
 Pregnancy serum
 phagocytosis and, 316
 polymorphonuclear leukocyte functions and, 316-325
 Primary degenerative joint disease of hand, 210-211, 215, 218
 clinical patterns of, 210
 inheritability of, 210
 pathogenesis, 210-211
 Progressive systemic sclerosis, *see* Scleroderma
 Proliferative synovitis, *see* Synovitis
 Propranolol
 effects on lymphocyte rosette formation, 767-774
 effects on rheumatoid factor, 118
 plant mitogen response and, 767-774
 Prostaglandin E, hyaluronate production and, 694-698
 Prostaglandins
 articular cartilage metabolism and, 909-917
 in rheumatoid arthritis, 909
 Proteoglycan
 analysis of, 579-580
 arthritic effect on biosynthesis of, 678
 in articular cartilage, 675-680
 Proteoglycan aggregates, 453-460, 942-949
 diphosphonate effect on, 942-949
 in potassium buffer, 456
 in sodium buffer, 455-456
 Pseudogout, colchicine treatment of, 596

Psoriasis, *see* Psoriatic arthritis

Psoriatic arthritis

- ankylosing spondylitis and, 628
- axial, 74
- chrysotherapy in, 513-515
- definitions of, 620
- deforming group of, 621
- distal joint involvement in, 620-621
- epidemiologic studies in, 628-629
- gold reactions in, 513-515
- indistinguishable group of, 621-622
- peripheral, 72-76
- Reiter's disease and, 622, 624
- seronegative polyarthritis and, 619-622

PSS, *see* Progressive systemic sclerosis

Purine nucleoside phosphorylase, deficiency of, 603-604

PWM, *see* Pokeweed mitogen

Pyarthrosis, acute hematogenous osteomyelitis progressing to, 968-971

Pyrophosphate

- activity of the synovial fluid, 447-452
- chondrocalcinosis and, 447-452

Q

QSS, *see* Quantitative sacroiliac scintigraphy

Quantitative sacroiliac scintigraphy

- antiinflammatory drugs, influence on, 236
- in Crohn's disease, 234-237

R

RA, *see* Rheumatoid arthritis

Radioimmunoassay

- anticollagen antibodies in rheumatoid arthritis demonstrated by, 243-248
- type C virus and, 267

Reflex sympathetic dystrophy syndrome, 838

Regional migratory osteoporosis, 834-838

- diagnosis of, 836
- reflex dystrophy syndrome contrasted with, 838
- treatment of, 838

Reiter's syndrome

- clinical associations with, 622, 624
- communicability of, 283-284
- epidemiologic studies in, 628
- HLA-B27 and, 885, 889
- HLA-C and, 886
- natural history of, 548-549
- probability theory and, 863-864
- psoriatic arthritis and, 622, 624
- seronegative polyarthritis and, 622, 624, 628

Renal transplantation, joint effusions after, 575

RF, *see* Rheumatoid factor

RF PFC, *see* Rheumatoid factor plaque-forming cell

Rheumatic diseases, *see also* specific disease names

- ambulatory patients and, 377-382
- classification of, 378
- frequency of, 380-382
- mortality versus disability in, 379-380
- national health survey of, 377-378
- severity of, 380-382
- terminology in, 378

Rheumatic fever, acute

- causes of, 652
- clinical manifestations of, 653

genetic studies in, 652

hereditary factors in, 653-655

HLA antigens in, 652-656

Rheumatoid arthritis

analgetics for, 564

ankylosing spondylitis with, 383-389

anti-antibody inhibition test in, 639, 641-642

anticollagen antibodies in, 243-248

antiglobulins in, 438-440

antiimmunoglobulins and, 120-128

antinuclear antibodies in, 645-651

articular collagenous tissues in, 516-527

articular involvement in, 577

azathioprine therapy in, 539

bacterial infections, susceptibility to, 111

buitressing of femoral neck in, 161-163

C4 in, 567-568

C-reactive protein in, 491

calcium ionophore and, 326-329

carpal tunnel syndrome and, 221-223

cervical disc disease in, 737-739

chrysotherapy in, 441, 513-515

circulating antibodies in, 249

collagen as autoantigen in, 243

Con-A and, 326-329

corticosteroid treatment of, 92-96, 110, 112

cost of, 827-833

cytotoxicity in, 601-602

diagnostic criteria for, 383

diffuse idiopathic skeletal hyperostosis and, 1-6

D-penicillamine and, 110, 112, 396

drug efficacy in, 171-172

estrogen and, 560-561

etiology of, 531-538

factor B in, 567-568

Felty's syndrome, comparison with, 310-315

gold therapy in, 441, 513-515

heterophile antibodies in, 634-638

HLA-B8 and, 338

HLA-Dw3 and, 338

HLA-Dw4 and, 558, 690

idiopathic hand flexor tenosynovitis and, 92-96

immune complexes in, 310-315, 639-644

immunodiffusion studies in, 311-312

immunoglobulin aggregates in, 516-527

immunoglobulins in, 331-334

immunologic features of, 120

immunopathologic studies of, 249-255

infectious etiology of, 531-538

influenza antibodies in, 239

inhibition experiments in, 245-246

intra-pericardial steroids in, 280

joint fluids in, 245

levamisole therapy in, 326-329, 589-590

light chains in, 438-440

lymphoblastoid cell lines in, 582-583

lymphocyte cell synthesis in, 330-336

lymphocyte response inhibition in, 171-172

lymphocytes to virus antigens in, 238-242

measles antibodies in, 239

mitogens and, 238, 241

mixed connective tissue disease and, 497-498, 502

monocyte antibody-dependent cell-mediated cytotoxicity in, 601-602

mycoplasma and, 533

nuclear antigens and, 540-541

ocular manifestations of, 595

oophorectomy and, 560-561

- pathogenesis of, 238, 252-253
 peptidoglycans and, 534-537
 peripheral blood lymphocytes in, 593-594
 PHA and, 326-329
 phagocytosis and, 107-113
 phytohemagglutinin and, 238
 polymorphonuclear leukocytes and, 107-113
 proteoglycan depletion of cartilage matrix in, 909
 radiographic abnormalities of, 1-5
 radioimmunoassay in, 243-248
 rheumatoid factor in, 330, 332, 438, 645-651
 robust type with diffuse idiopathic skeletal hyperostosis, 1
 rubella and, 240
 serologic studies in, 109-110
 serum antiimmunoglobulins in, 120-128
 shoulder swelling in, 145-147
 subacromial bursitis, secondary to, 145-147
 subacute bacterial endocarditis and, 438-440
 susceptibility to, 556
 synovial cells susceptibility to ADCC, 97-105
 synovial fluids in, 243-248, 249-255
 synovial inflammation in, 97, 556
 synovitis and, 330, 438, 560-561
 tear lysozyme increase in, 595
 tenosynovitis and, 92-96
 ultracentrifugation studies in, 312-313
 viral infections and, 238, 533-534
 virus antigens in, 238-242
 wrist involvement in, 555
- Rheumatoid factor plaque-forming cell (RF PFC), effect of cyclic nucleotides on, 118
- Rheumatoid factor (RF)
 antinuclear antibodies and, 645-651
 assay, automated, 224-228
 benign rheumatoid nodules, and, 930-934
 complement-fixing in juvenile rheumatoid arthritis, 579
 cyclic nucleotides effect on, 118
 DNA-protein and, 540
 drug effects on, 114-119
 gout and, 544
 hemolytic plaque-forming assay for, 820-821
 HLA-Dw4 and, 690-693
 infection relationship to in rheumatoid arthritis, 111
 in juvenile rheumatoid arthritis, 579, 935-941
 latex agglutination test for, 224, 226
 lymphocyte reaction in healthy women with, 690-693
 lymphocyte release of, 115
 and phagocytic performance interference, 111
 in plaque-forming cell assay, 114-119
 propranolol effect on, 118
 in rheumatoid arthritis, 111, 226-228, 645-651
 relative reactivities of in serum and cells, 820-826
- Rheumatoid plaque-forming cell, 114-119
- Rheumatoid synovial cells
 antibody against, 102
 antibody-dependent cell-mediated cytotoxicity (ADCC), susceptibility to, 97-105
 susceptibility to lysis, 100
 viral-like particles in, 559
- Rheumatoid synovitis, *see also* Synovitis
 analgesics for, 564
- Rheumatoid vasculitis, ankylosing spondylitis with, 383-389
- Ribonuclease sensitive antigen, 608
- RMO, *see* Regional migratory osteoporosis
- RS, *see* Reiter's syndrome
- Rumalon R, for osteoarthritis, 494-496
- S**
- Salicylates, *see also* Aspirin
 in juvenile rheumatoid arthritis, 129-132
 measurement of concentration of, 129-132
- Sarcoidosis
 corticosteroid therapy in, 271
 course of, 275
 osseous involvement in, 271
 paravertebral ossification and, 271-276
 suppressor cell function in, 561
- Satellite arthritis clinic, 727-730
 advantages of, 728-729
 problems of, 729
- SBE, *see* Subacute bacterial endocarditis
- Scleroderma
 cardiomyopathy in, 609-611
 clinical criteria for, 65, 576-577
 collagen in, 418-428
 corticosteroid therapy in, 69
 definition of, 62-63
 electromyography and, 993-994
 electron microscopy and, 421-423
 fibrinogen turnover in, 343-347
 gastrointestinal symptoms in, 811-819
 histology of, 421
 immunofluorescence and, 423
 lymphocytes and, 423
 and mixed connective tissue disease, 576, 811-819
 model for, 557
 muscle disease and, 62-71
 myopathies and, 64, 66
 renal crisis in, 600-601
 stages in development of, 418
 vascular abnormalities in, 346
- SCN, *see* Subcutaneous nodule
- SD, *see* Scleroderma
- Septic arthritis
 diagnostic aid in, 774-779
 in multiple myeloma, 150
 radiographic features in, 998-999
 synovial fluid lactic acid in, 774-779
- Septic discitis, 574-575
- Septic synovitis, acute hematogenous osteomyelitis progressing to, 968-971
- Seronegative polyarthritis
 Behcet's syndrome and, 623, 626
 clinical association with, 622-626
 concept of, 622-630
 Crohn's disease and, 623, 625-626, 628-629
 epidemiologic studies in, 627-629
 familial aggregation of, 626-627
 histocompatibility antigens and, 629
 psoriatic arthritis and, 619-622, 624, 628
 Reiter's disease and, 622, 624, 628
 ulcerative colitis and, 622-625, 629
 Whipple's disease and, 623-624
- Seronegative spondylarthritis, *see* Seronegative polyarthritis
- Serum antiimmunoglobulins
 in normal individuals, 120-128
 in osteoarthritis, 120-128
 in rheumatoid arthritis, 120-128
 reactive with human and rabbit IgG, 120-128
 in rheumatic fever, 120-128
- Shoulder swelling, in rheumatoid arthritis, 147-149
- Sicca syndrome
 B-lymphocyte antigens in, 580-581
 circulating immune complexes in, 580
 glomerulonephritis in, 580
 nuclear antigens and, 810
- Sickle cell disease
 systemic lupus erythematosus and, 862-863
 uric acid overproduction in, 553-554
- Sjögren's syndrome
 age of onset of, 385
 chrysotherapy in, 790

- definition of, 584
- HLA-B8 and, 337-342
- HLA-Dw3 and, 337-342
- lymphoma in, 585
- severity of, 340-341
- sex distribution of, 385
- SLE, *see* Systemic lupus erythematosus
- SLE-PBL, *see* Peripheral blood lymphocytes in systemic lupus erythematosus
- Sodium warfarin and hemarthrosis, 740
- Spinal pseudoarthrosis, 485-490
- Spondylarthritis
 - HLA-B27 in, 889
 - HLA-Cw1 and, 889-895
 - HLA-Cw2 in, 889-895
- Steroids, *see* Corticosteroids
- Subacromial bursitis, rheumatoid arthritis secondary to, 145-147
- Subacute bacterial endocarditis
 - antiglobulins in, 438-440
 - light chains in, 438-440
 - rheumatoid arthritis and, 438-440
- Subcutaneous nodules
 - in children without juvenile rheumatoid arthritis, 930
 - clinical significance in rheumatoid arthritis, 589
 - hemochromatosis and, 844-848
- Subperiosteal bone apposition, *see* Buttressing
- Sulfanilamidoindazole arthritis, 681-689
- Suppressor lymphocyte, immunodeficiency associated with in mice, 578
- Synovial cells
 - growth kinetics of, 461-466
 - viral-like particles in rheumatoid, 559
- Synovial fluid cells, in systemic lupus erythematosus, 590
- Synovial fluid
 - boundary lubricating ability of, 754-760
 - in degenerative joint disease, 754-760
 - gonococcal arthritis and, 775-776
 - hydroxyapatite crystals in, 563
 - lactic acid of, 774-779
 - in mixed cryoglobulinemia, 740-741
 - platelets in, 607-608
 - septic arthritis and, 774-779
- Synovitis, *see also* Rheumatoid synovitis
 - analgesics for, 564
 - biochemical observations of, 137-144
 - gout and, 544
 - in hemophilia, 137-144
 - immunopathology of, 97
 - morphologic observations of, 137-144
 - oophorectomy in, 560-561
 - proliferative, 137-144
 - splinter-induced, 278
- Systemic lupus erythematosus (SLE)
 - abdominal syndromes in, 606
 - acetylation phenotypes, distribution in, 192-195
 - active urinary sediment effect on infection in, 42
 - acute pericarditis in, 972
 - age distribution in, 473-479
 - androgenic status of males with, 665-668
 - anti-DNA antibodies in, 45-50, 289-293, 543, 602, 950
 - anti-DNA complexes in, 17-22, 24-25
 - anti-DNA synthesis in, 582
 - antibodies
 - antilymphocyte in, 23-27, 289
 - antinuclear in, 55, 186, 590-591
 - antipolynucleotide and, 23-27
 - antiviral in, 23-27, 51
 - to histone in, 556-557
 - to neuronal cells in, 546
 - autoimmune diseases and, 51
 - autoimmune neutropenia in, 504-512
 - azathioprine in, 39-40
 - C-reactive protein elevations in, 605
 - C2 deficiency and, 28-35
 - C3 deficiency and, 40-42
 - C3 serum levels in, 178, 602
 - cardiovascular complications of, 972-974
 - causes of, 266
 - cellular antigen preparations in, 873-879
 - central nervous system dysfunction in, 289-294
 - cerebral involvement in, 597-598
 - in children, 599-600
 - clinically quiescent, 559
 - Clq-sepharose eluates characterization in, 20
 - co-culture experiments in, 54-55
 - complement fixation reactivities in, 873
 - complement, role in, 177
 - constrictive pericarditis in, 972-974
 - corticosteroid therapy, 39, 112, 262-263
 - central retinal vein occlusion in, 839-843
 - disease activity in, 539-540, 568-569
 - DNA/anti-DNA complexes in, 17-22
 - DNA binding and, 552
 - DNA complexes in, 17-22
 - DNA structure in, 407
 - diffuse proliferative glomerulonephritis and, 577-578
 - drug-induced, 192-194, 556-557
 - estrogen metabolism in, 306
 - female predominance in, 849-852
 - fever in, 594-595
 - fibrinogen in, 343
 - Frentizole therapy in, 599
 - genetic implications of antibodies in, 23-27
 - genetic information in tissues of, 880-884
 - genetic predisposition to, 183-191, 306, 586
 - gross splenomegaly in, 866
 - herpes zoster in, 798-802
 - histone antibodies in, 556-557
 - HLA profiles in, 183-191
 - hormonal factors in, 665-668
 - household contact and antibodies in, 24-25
 - hydralazine effects in, 565-566
 - immune complexes in, 107, 539-540
 - immune functions in, 657-664
 - immunoglobulin level in, 27
 - immunologic sex differences in, 849-852
 - immunoperoxidase staining of choroid plexus in, 547
 - infection
 - as cause of death in, 37
 - frequency in, 37-44
 - influenza antibodies in, 25
 - inhibition of natural killing of tumor cell line in, 592
 - ischemic necrosis of bone in, 606
 - kidney disease in, 578-579
 - Klinefelter's syndrome and, 306-309
 - laboratory personnel, immune reactivity of, 587
 - Legionnaires' disease in, 975-977
 - leukocyte counts and effect on infection in, 41
 - leukopenia in, 504
 - lupus nephritis, effect on infection in, 41-43
 - lymphocyte counts in, 297-299
 - lymphocytotoxic antibodies in, 189-190, 560
 - lymphocytotoxicity of cerebrospinal fluid in, 603
 - lymphopenia in, 295-305
 - males with, 665-668
 - manifestations of, 8-11
 - measles antibody in, 25
 - membrane attack complex and, 177-182
 - migrainous phenomena in, 7-16
 - monocytotoxic antibodies in, 170-171
- ARA Preliminary Criteria for Classification of, Suggested revision of, 602

monozygotic twins discordant for, 306-309
 mortality statistics in, 473-479
 myasthenia gravis and, 306-309
 myeloma and, 260-265
 nephritis in, *see* Lupus nephritis
 neurologic manifestations in association with migrainous phenomena, 9-13
 neuropsychiatric manifestations of, 289-294
 neutropenia in, 504-512
 neutrophilic inclusions in, 566
 nuclear antigens and, 804
 ocular disease in, 839-843
 oral mucosal ulceration in, 58-61
 orncornaviruses and, 266-270, 584, 880-884
 pathogenesis of, 295, 306, 480-484, 657, 880, 950
 pericarditis in, 972-974
 peripheral blood leukocytes in, 177-182
 peripheral blood lymphocytes in, 582
 phagocytosis and, 107-113
 plasmapheresis in, 567
 pokeweed mitogen-stimulated cultures and, 51-56
 polymorphonuclear leukocytes and, 107-113, 180
 race distribution in, 473-479
 renal disease activity in, 574
 reticuloendothelial receptor function in, 563
 serologic studies in, 109-110, 189, 289-294
 serologically active, 559
 sex distribution in, 306, 473-479, 665, 849-852
 sex effects on, 480-484
 sex hormones in, 306-308
 sickle cell disease and, 862-863
 suppressor macrophages in, 600
 symptomatic myasthenia gravis and, 306-309
 symptoms of, 262
 synergy of sex and race in, 478, 480
 synovial fluid cells in, 590
 T cell dysfunction in, 56
 T cell suppressor function in, 657-664
 T gamma cells, decreased levels of in, 553
 testosterone levels in, 307-308
 thymus, role of in, 492-493
 treatment decisions in, 601
 type C oncornavirus-related genetic information in, 880-884
 type C viruses and, 266-270, 584
 uremia and effect on infection in, 41-43
 urinary prostaglandin E in, 570
 vascular dysfunction in as cause of migrainous phenomena, 16
 viral etiology of, 880
 virus antigen preparations in, 873-879
 Westergren erythrocyte sedimentation rate effect on infection in, 40-41
 Systemic sclerosis, *see* Scleroderma

T

T cell, in systemic lupus erythematosus, 56, 553, 657-664
 Temporal arteriography, 780-784
 Temporal arteritis, 362-366
 Tenosynovitis
 carpal tunnel syndrome and, 223
 hemochromatosis and, 844-848
 Thalassemia minor, aseptic necrosis and, 280
 THR, *see* Total hip replacement
 Thrombocytopenia, caused by colchicine, 733
 Thrombopenia, in mixed connective tissue disease, 995-997
 Thymosin treatment
 antibodies to, 198-199

 effect on cells, 199
 in New Zealand mice, 196-203
 Tophi, immunoglobulins in, 353-361
 Total hip replacement (THR)
 ambulatory status after, 403
 complications following, 404-405
 indications for, 401-406
 in juvenile rheumatoid arthritis, 401-406
 motivation of patient, importance of, 404
 physical therapy following, 404
 value of, 401-406
 Transverse myelitis, in mixed connective tissue disease, 982-986
 Traumatic arthritis
 fat droplets in synovial fluid, 76-80
 synovial fluid leukocytosis in, 76-80
 Triamcinolone for flexor tenosynovitis, 94
 Type C virus
 characteristics of, 266
 detection of, 267
 molecular hybridization as test for, 267
 radioimmunoassay for, 267
 systemic lupus erythematosus and, 266-270

U

Ulceration, oral mucosal in systemic lupus erythematosus, 58-61
 Ulcerative colitis
 clinical associations with, 622-625
 epidemiologic studies in, 629
 Urate solubility
 buffer cation effect on, 455-456
 enhancement of by connective tissue, 453-460
 gout and, 453
 potassium buffer and, 456
 proteoglycan aggregates effect on, 453-460
 sodium buffer and, 456
 Uremia and systemic lupus erythematosus, 41, 43
 Urinary sediment, effect on infection in systemic lupus erythematosus, 42

V

Vertebral ankylosing hyperostosis, *see* Forestier's disease
 Vertebral sarcoidosis, paravertebral ossification and, 271-276
 Vitamin D, and osteomalacia, 715, 722

W

Wegener's granulomatosis, parotid nodules in, 864-865
 Westergren erythrocyte sedimentation rate, effect on infection in systemic lupus erythematosus, 40-41
 Whipple's disease, clinical associations with, 623-624
 Wrist, *see also* Carpal tunnel syndrome
 in rheumatoid arthritis, 555
 surgical stabilization of rheumatoid, 555

Y

Yersinia infection
 antiepithelial antibodies in, 904-908
 clinical manifestations of, 907
 gammaglobulin concentrations in, 905
 humoral immune stimulation in, 904-908
 sex distribution in, 907

